WO2022225779A1 - Methods and compositions for promoting wound healing - Google Patents
Methods and compositions for promoting wound healing Download PDFInfo
- Publication number
- WO2022225779A1 WO2022225779A1 PCT/US2022/024745 US2022024745W WO2022225779A1 WO 2022225779 A1 WO2022225779 A1 WO 2022225779A1 US 2022024745 W US2022024745 W US 2022024745W WO 2022225779 A1 WO2022225779 A1 WO 2022225779A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hmb
- hmo
- nutritional composition
- lacto
- acidic
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 124
- 238000000034 method Methods 0.000 title claims abstract description 56
- 230000029663 wound healing Effects 0.000 title claims abstract description 38
- 230000001737 promoting effect Effects 0.000 title claims abstract description 12
- 235000016709 nutrition Nutrition 0.000 claims abstract description 106
- AXFYFNCPONWUHW-UHFFFAOYSA-N 3-hydroxyisovaleric acid Chemical compound CC(C)(O)CC(O)=O AXFYFNCPONWUHW-UHFFFAOYSA-N 0.000 claims abstract description 96
- 230000007935 neutral effect Effects 0.000 claims abstract description 44
- 230000002378 acidificating effect Effects 0.000 claims abstract description 42
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000004475 Arginine Substances 0.000 claims abstract description 38
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims abstract description 38
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims abstract description 26
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 claims abstract description 26
- 229920001542 oligosaccharide Polymers 0.000 claims abstract description 10
- 235000020256 human milk Nutrition 0.000 claims abstract description 7
- 150000002482 oligosaccharides Chemical class 0.000 claims abstract description 7
- 210000004251 human milk Anatomy 0.000 claims abstract description 6
- AXQLFFDZXPOFPO-UHFFFAOYSA-N UNPD216 Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC(C1O)C(O)C(CO)OC1OC1C(O)C(O)C(O)OC1CO AXQLFFDZXPOFPO-UHFFFAOYSA-N 0.000 claims description 16
- USIPEGYTBGEPJN-UHFFFAOYSA-N lacto-N-tetraose Natural products O1C(CO)C(O)C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(=O)C)C1OC1C(O)C(CO)OC(OC(C(O)CO)C(O)C(O)C=O)C1O USIPEGYTBGEPJN-UHFFFAOYSA-N 0.000 claims description 16
- AXQLFFDZXPOFPO-UNTPKZLMSA-N beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O([C@@H]1O[C@H](CO)[C@H](O)[C@@H]([C@H]1O)O[C@H]1[C@@H]([C@H]([C@H](O)[C@@H](CO)O1)O[C@H]1[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O1)O)NC(=O)C)[C@H]1[C@H](O)[C@@H](O)[C@H](O)O[C@@H]1CO AXQLFFDZXPOFPO-UNTPKZLMSA-N 0.000 claims description 15
- TYALNJQZQRNQNQ-JLYOMPFMSA-N alpha-Neup5Ac-(2->6)-beta-D-Galp-(1->4)-beta-D-Glcp Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O1 TYALNJQZQRNQNQ-JLYOMPFMSA-N 0.000 claims description 14
- 150000001720 carbohydrates Chemical class 0.000 claims description 14
- IEQCXFNWPAHHQR-UHFFFAOYSA-N lacto-N-neotetraose Natural products OCC1OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O IEQCXFNWPAHHQR-UHFFFAOYSA-N 0.000 claims description 14
- 229940062780 lacto-n-neotetraose Drugs 0.000 claims description 14
- RBMYDHMFFAVMMM-PLQWBNBWSA-N neolactotetraose Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O RBMYDHMFFAVMMM-PLQWBNBWSA-N 0.000 claims description 14
- SNFSYLYCDAVZGP-OLAZETNGSA-N 2'-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O[C@H](CO)[C@H](O)[C@@H]1O SNFSYLYCDAVZGP-OLAZETNGSA-N 0.000 claims description 13
- SNFSYLYCDAVZGP-UHFFFAOYSA-N UNPD26986 Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(OC(O)C(O)C2O)CO)OC(CO)C(O)C1O SNFSYLYCDAVZGP-UHFFFAOYSA-N 0.000 claims description 13
- DVGKRPYUFRZAQW-UHFFFAOYSA-N 3 prime Natural products CC(=O)NC1OC(CC(O)C1C(O)C(O)CO)(OC2C(O)C(CO)OC(OC3C(O)C(O)C(O)OC3CO)C2O)C(=O)O DVGKRPYUFRZAQW-UHFFFAOYSA-N 0.000 claims description 11
- -1 HMB lactone Chemical class 0.000 claims description 11
- 229910052791 calcium Inorganic materials 0.000 claims description 11
- 239000011575 calcium Substances 0.000 claims description 11
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 claims description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 7
- 102000008186 Collagen Human genes 0.000 claims description 6
- 108010035532 Collagen Proteins 0.000 claims description 6
- 239000002253 acid Substances 0.000 claims description 5
- 229920001436 collagen Polymers 0.000 claims description 5
- TYALNJQZQRNQNQ-UHFFFAOYSA-N #alpha;2,6-sialyllactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OCC1C(O)C(O)C(O)C(OC2C(C(O)C(O)OC2CO)O)O1 TYALNJQZQRNQNQ-UHFFFAOYSA-N 0.000 claims description 4
- CILYIEBUXJIHCO-UHFFFAOYSA-N 102778-91-6 Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC2C(C(O)C(O)OC2CO)O)OC(CO)C1O CILYIEBUXJIHCO-UHFFFAOYSA-N 0.000 claims description 4
- 229940062827 2'-fucosyllactose Drugs 0.000 claims description 4
- HWHQUWQCBPAQQH-UHFFFAOYSA-N 2-O-alpha-L-Fucosyl-lactose Natural products OC1C(O)C(O)C(C)OC1OC1C(O)C(O)C(CO)OC1OC(C(O)CO)C(O)C(O)C=O HWHQUWQCBPAQQH-UHFFFAOYSA-N 0.000 claims description 4
- CILYIEBUXJIHCO-UITFWXMXSA-N N-acetyl-alpha-neuraminyl-(2->3)-beta-D-galactosyl-(1->4)-beta-D-glucose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)O[C@@H]2CO)O)O[C@H](CO)[C@@H]1O CILYIEBUXJIHCO-UITFWXMXSA-N 0.000 claims description 4
- OIZGSVFYNBZVIK-UHFFFAOYSA-N N-acetylneuraminosyl-D-lactose Natural products O1C(C(O)C(O)CO)C(NC(=O)C)C(O)CC1(C(O)=O)OC1C(O)C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C1O OIZGSVFYNBZVIK-UHFFFAOYSA-N 0.000 claims description 4
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 4
- 229910052700 potassium Inorganic materials 0.000 claims description 4
- 239000011591 potassium Substances 0.000 claims description 4
- WJPIUUDKRHCAEL-UHFFFAOYSA-N 3FL Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(O)C1O WJPIUUDKRHCAEL-UHFFFAOYSA-N 0.000 claims description 3
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052783 alkali metal Inorganic materials 0.000 claims description 3
- 150000001340 alkali metals Chemical class 0.000 claims description 3
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims description 3
- 150000001342 alkaline earth metals Chemical class 0.000 claims description 3
- 229910052804 chromium Inorganic materials 0.000 claims description 3
- 239000011651 chromium Substances 0.000 claims description 3
- 229910052749 magnesium Inorganic materials 0.000 claims description 3
- 239000011777 magnesium Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- 238000004977 Hueckel calculation Methods 0.000 description 32
- 208000027418 Wounds and injury Diseases 0.000 description 23
- 235000018102 proteins Nutrition 0.000 description 21
- 102000004169 proteins and genes Human genes 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 206010052428 Wound Diseases 0.000 description 20
- 239000007788 liquid Substances 0.000 description 14
- 235000014633 carbohydrates Nutrition 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 239000003921 oil Substances 0.000 description 11
- 235000019198 oils Nutrition 0.000 description 11
- 210000002950 fibroblast Anatomy 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 8
- PDWGIAAFQACISG-QZBWVFMZSA-N beta-D-Gal-(1->3)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O PDWGIAAFQACISG-QZBWVFMZSA-N 0.000 description 8
- 235000008504 concentrate Nutrition 0.000 description 7
- 239000012141 concentrate Substances 0.000 description 7
- 235000019197 fats Nutrition 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 240000008042 Zea mays Species 0.000 description 6
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 6
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 6
- 235000005822 corn Nutrition 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 108010009736 Protein Hydrolysates Proteins 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 230000023597 hemostasis Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 239000003531 protein hydrolysate Substances 0.000 description 5
- WJPIUUDKRHCAEL-YVEAQFMBSA-N 3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)OC(O)[C@@H]1O WJPIUUDKRHCAEL-YVEAQFMBSA-N 0.000 description 4
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- PNNNRSAQSRJVSB-UHFFFAOYSA-N L-rhamnose Natural products CC(O)C(O)C(O)C(O)C=O PNNNRSAQSRJVSB-UHFFFAOYSA-N 0.000 description 4
- 229920002774 Maltodextrin Polymers 0.000 description 4
- 239000005913 Maltodextrin Substances 0.000 description 4
- 240000007594 Oryza sativa Species 0.000 description 4
- 235000007164 Oryza sativa Nutrition 0.000 description 4
- DTOSIQBPPRVQHS-PDBXOOCHSA-N alpha-linolenic acid Chemical compound CC\C=C/C\C=C/C\C=C/CCCCCCCC(O)=O DTOSIQBPPRVQHS-PDBXOOCHSA-N 0.000 description 4
- 238000001516 cell proliferation assay Methods 0.000 description 4
- UUZWLWYXBNTJDG-UHFFFAOYSA-N disialyllacto-n-hexaose i Chemical compound C1C(C(O)C(O)CO)C(NC(=O)C)C(O)OC1(C(O)=O)OC1C(O)C(OC2C(C(OC3C(C(OC(C(O)CO)C(O)C(O)C=O)OC(COC4C(C(O)C(OC5C(C(O)C(O)C(COC6(OC(C(NC(C)=O)C(O)C6)C(O)C(O)CO)C(O)=O)O5)O)C(CO)O4)NC(C)=O)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C1O UUZWLWYXBNTJDG-UHFFFAOYSA-N 0.000 description 4
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 4
- 229940035034 maltodextrin Drugs 0.000 description 4
- 229950006780 n-acetylglucosamine Drugs 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 235000009566 rice Nutrition 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 235000010469 Glycine max Nutrition 0.000 description 3
- 108010011756 Milk Proteins Proteins 0.000 description 3
- 102000014171 Milk Proteins Human genes 0.000 description 3
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 3
- MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 3
- 108010084695 Pea Proteins Proteins 0.000 description 3
- 235000019485 Safflower oil Nutrition 0.000 description 3
- QUOQJNYANJQSDA-MHQSSNGYSA-N Sialyllacto-N-tetraose a Chemical compound O1C([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](OC2[C@H]([C@H](OC3[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@@H]1O QUOQJNYANJQSDA-MHQSSNGYSA-N 0.000 description 3
- SFMRPVLZMVJKGZ-JRZQLMJNSA-N Sialyllacto-N-tetraose b Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]2O)O)O1 SFMRPVLZMVJKGZ-JRZQLMJNSA-N 0.000 description 3
- 235000010749 Vicia faba Nutrition 0.000 description 3
- 240000006677 Vicia faba Species 0.000 description 3
- 235000002098 Vicia faba var. major Nutrition 0.000 description 3
- 229930003427 Vitamin E Natural products 0.000 description 3
- 108010046377 Whey Proteins Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000003240 coconut oil Substances 0.000 description 3
- 235000019864 coconut oil Nutrition 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- FCIROHDMPFOSFG-LAVSNGQLSA-N disialyllacto-N-tetraose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)OC[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@H]3[C@@H]([C@@H](O)C(O)O[C@@H]3CO)O)O[C@H](CO)[C@@H]2O)O)O1 FCIROHDMPFOSFG-LAVSNGQLSA-N 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 235000019702 pea protein Nutrition 0.000 description 3
- 235000005713 safflower oil Nutrition 0.000 description 3
- 239000003813 safflower oil Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 235000019165 vitamin E Nutrition 0.000 description 3
- 239000011709 vitamin E Substances 0.000 description 3
- 229940046009 vitamin E Drugs 0.000 description 3
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N 2,3,4,5-tetrahydroxypentanal Chemical compound OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- FNCPZGGSTQEGGK-DRSOAOOLSA-N 3'-Sialyl-3-fucosyllactose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]([C@@H](O)C=O)[C@@H]([C@H](O)CO)O[C@H]1[C@H](O)[C@@H](O[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O1 FNCPZGGSTQEGGK-DRSOAOOLSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- 108010076119 Caseins Proteins 0.000 description 2
- 102000011632 Caseins Human genes 0.000 description 2
- SHZGCJCMOBCMKK-SVZMEOIVSA-N D-fucopyranose Chemical compound C[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O SHZGCJCMOBCMKK-SVZMEOIVSA-N 0.000 description 2
- 208000008960 Diabetic foot Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- SHZGCJCMOBCMKK-PQMKYFCFSA-N L-Fucose Natural products C[C@H]1O[C@H](O)[C@@H](O)[C@@H](O)[C@@H]1O SHZGCJCMOBCMKK-PQMKYFCFSA-N 0.000 description 2
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 2
- TVVLIFCVJJSLBL-SEHWTJTBSA-N Lacto-N-fucopentaose V Chemical compound O[C@H]1C(O)C(O)[C@H](C)O[C@H]1OC([C@@H](O)C=O)[C@@H](C(O)CO)O[C@H]1[C@H](O)[C@@H](OC2[C@@H](C(OC3[C@@H](C(O)C(O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@@H](CO)O1 TVVLIFCVJJSLBL-SEHWTJTBSA-N 0.000 description 2
- BRHHWBDLMUBZQQ-JZEMXWCPSA-N Lactodifucotetraose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@@H]([C@H](O)[C@H](O)CO)[C@H](C=O)O[C@@H]1[C@H](O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 BRHHWBDLMUBZQQ-JZEMXWCPSA-N 0.000 description 2
- LKOHREGGXUJGKC-UHFFFAOYSA-N Lactodifucotetraose Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)OC2CO)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O LKOHREGGXUJGKC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- GKEWHGPIQCSUCC-JJGOEJEFSA-N Monofucosyllacto-N-hexaose Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)C[C@@H](OO[C@@H]2[C@@H]([C@H](O[C@H]3[C@@H](C(O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O2)O)[C@@H]1NC(C)=O GKEWHGPIQCSUCC-JJGOEJEFSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- SXMGGNXBTZBGLU-IBUUTZGMSA-N Sialyllacto-N-neotetraose c Chemical compound O([C@H]([C@@H]([C@@H](O)[C@H]1O)O)O[C@H]2[C@H](O)[C@H]([C@@H](O[C@@H]2CO)O[C@@H]2[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]2O)O)NC(=O)C)C1CO[C@]1(C(O)=O)C[C@H](O)[C@@H](NC(C)=O)[C@H]([C@H](O)[C@H](O)CO)O1 SXMGGNXBTZBGLU-IBUUTZGMSA-N 0.000 description 2
- 108010073771 Soybean Proteins Proteins 0.000 description 2
- 239000004376 Sucralose Substances 0.000 description 2
- 208000002847 Surgical Wound Diseases 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102000007544 Whey Proteins Human genes 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000619 acesulfame-K Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 2
- FZIVHOUANIQOMU-YIHIYSSUSA-N alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)O[C@H](CO)[C@H]2O)NC(C)=O)O[C@H](CO)[C@H](O)[C@@H]1O FZIVHOUANIQOMU-YIHIYSSUSA-N 0.000 description 2
- CMQZRJBJDCVIEY-JEOLMMCMSA-N alpha-L-Fucp-(1->3)-[beta-D-Galp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O[C@@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)[C@@H]1NC(C)=O CMQZRJBJDCVIEY-JEOLMMCMSA-N 0.000 description 2
- RQNFGIWYOACERD-OCQMRBNYSA-N alpha-L-Fucp-(1->4)-[alpha-L-Fucp-(1->2)-beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@@H]2NC(C)=O)O[C@H]2[C@H]([C@H](O)[C@H](O)[C@H](C)O2)O)O[C@H](CO)[C@H](O)[C@@H]1O RQNFGIWYOACERD-OCQMRBNYSA-N 0.000 description 2
- DUKURNFHYQXCJG-JEOLMMCMSA-N alpha-L-Fucp-(1->4)-[beta-D-Galp-(1->3)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO DUKURNFHYQXCJG-JEOLMMCMSA-N 0.000 description 2
- RPSBVJXBTXEJJG-LURNZOHQSA-N alpha-N-acetylneuraminyl-(2->6)-beta-D-galactosyl-(1->4)-N-acetyl-beta-D-glucosamine Chemical compound O[C@@H]1[C@@H](NC(=O)C)[C@H](O)O[C@H](CO)[C@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO[C@]2(O[C@H]([C@H](NC(C)=O)[C@@H](O)C2)[C@H](O)[C@H](O)CO)C(O)=O)O1 RPSBVJXBTXEJJG-LURNZOHQSA-N 0.000 description 2
- 235000020661 alpha-linolenic acid Nutrition 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- NPPRJALWPIXIHO-PNCMPRLYSA-N beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->3)-[beta-D-Gal-(1->4)-beta-D-GlcNAc-(1->6)]-beta-D-Gal-(1->4)-D-Glc Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)OC[C@@H]1[C@@H]([C@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O[C@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)[C@@H](CO)O2)NC(C)=O)[C@@H](O)[C@H](O[C@@H]2[C@H](OC(O)[C@H](O)[C@H]2O)CO)O1)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O NPPRJALWPIXIHO-PNCMPRLYSA-N 0.000 description 2
- DMYPRRDPOMGEAK-XWDFSUOISA-N beta-D-Galp-(1->3)-[alpha-L-Fucp-(1->4)]-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-[alpha-L-Fucp-(1->3)]-D-Glcp Chemical compound O[C@H]1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@H](O[C@H]4[C@H]([C@H](O)[C@H](O)[C@H](C)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)OC(O)[C@@H]1O DMYPRRDPOMGEAK-XWDFSUOISA-N 0.000 description 2
- UTVHXMGRNOOVTB-IXBJWXGWSA-N beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-beta-D-GlcpNAc-(1->3)-beta-D-Galp-(1->4)-D-Glcp Chemical compound O([C@H]1[C@H](O)[C@H]([C@@H](O[C@@H]1CO)O[C@@H]1[C@H]([C@H](O[C@@H]2[C@H](O[C@@H](O[C@@H]3[C@H]([C@H](O[C@@H]4[C@H](OC(O)[C@H](O)[C@H]4O)CO)O[C@H](CO)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)CO)O[C@H](CO)[C@@H]1O)O)NC(=O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O UTVHXMGRNOOVTB-IXBJWXGWSA-N 0.000 description 2
- SQVRNKJHWKZAKO-UHFFFAOYSA-N beta-N-Acetyl-D-neuraminic acid Natural products CC(=O)NC1C(O)CC(O)(C(O)=O)OC1C(O)C(O)CO SQVRNKJHWKZAKO-UHFFFAOYSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 239000000828 canola oil Substances 0.000 description 2
- 235000019519 canola oil Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000005687 corn oil Nutrition 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- SUSQQDGHFAOUBW-PVLJGHBYSA-N difucosyllacto-n-hexaose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](C)O[C@@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](O[C@@H]2[C@H]([C@H](O[C@@H]3[C@H](OC(O)[C@H](O)[C@H]3O)CO)O[C@H](CO[C@H]3[C@@H]([C@@H](O[C@@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](C)O4)O)[C@H](O[C@H]4[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O4)O)[C@@H](CO)O3)NC(C)=O)[C@@H]2O)O)O[C@@H]1CO SUSQQDGHFAOUBW-PVLJGHBYSA-N 0.000 description 2
- BCUMESVDMXHZRL-UHFFFAOYSA-N difucosyllacto-n-hexaose i Chemical compound OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC3C(C(NC(C)=O)C(OC4C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C4O)O)OC3CO)OC3C(C(O)C(O)C(C)O3)O)OC(CO)C2O)O)OC1CO BCUMESVDMXHZRL-UHFFFAOYSA-N 0.000 description 2
- KNWXPODBRXAWBX-PFNBIPCHSA-N disialyllacto-n-fucopentaose ii Chemical compound OC1[C@H](O)[C@H](O)[C@H](C)O[C@H]1O[C@H]1[C@H](O[C@H]2[C@@H]([C@@H](O[C@]3(O[C@H]([C@H](NC(C)=O)[C@@H](O)C3)[C@H](O)[C@H](O)CO)C(O)=O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](NC(C)=O)[C@H](OC2[C@H]([C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]2O)O)O[C@@H]1CO[C@@]1(C(O)=O)O[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C1 KNWXPODBRXAWBX-PFNBIPCHSA-N 0.000 description 2
- DUVKOIQTTLSEBM-UHFFFAOYSA-N disialyllacto-n-hexaose ii Chemical compound OCC1OC(OCC2C(C(OC3C(C(OC4C(C(OC5(OC(C(NC(C)=O)C(O)C5)C(O)C(O)CO)C(O)=O)C(O)C(CO)O4)O)C(O)C(COC4(OC(C(NC(C)=O)C(O)C4)C(O)C(O)CO)C(O)=O)O3)NC(C)=O)C(O)C(OC(C(O)CO)C(O)C(O)C=O)O2)O)C(NC(=O)C)C(O)C1OC1OC(CO)C(O)C(O)C1O DUVKOIQTTLSEBM-UHFFFAOYSA-N 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 230000019305 fibroblast migration Effects 0.000 description 2
- 208000031169 hemorrhagic disease Diseases 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- RQNFGIWYOACERD-UHFFFAOYSA-N lacto-N-Difucosylhexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O RQNFGIWYOACERD-UHFFFAOYSA-N 0.000 description 2
- OQIUPKPUOLIHHS-UHFFFAOYSA-N lacto-N-difucohexaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(CO)OC(OC3C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C3O)O)C2NC(C)=O)OC2C(C(O)C(O)C(C)O2)O)OC(CO)C(O)C1O OQIUPKPUOLIHHS-UHFFFAOYSA-N 0.000 description 2
- DMYPRRDPOMGEAK-UHFFFAOYSA-N lacto-N-difucohexaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(C(O)C(O)C(CO)O4)O)C(OC4C(C(O)C(O)C(C)O4)O)C(CO)O3)NC(C)=O)C(O)C(CO)O2)O)C(CO)OC(O)C1O DMYPRRDPOMGEAK-UHFFFAOYSA-N 0.000 description 2
- FZIVHOUANIQOMU-UHFFFAOYSA-N lacto-N-fucopentaose I Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(OC3C(C(OC4C(OC(O)C(O)C4O)CO)OC(CO)C3O)O)OC(CO)C2O)NC(C)=O)OC(CO)C(O)C1O FZIVHOUANIQOMU-UHFFFAOYSA-N 0.000 description 2
- FKADDOYBRRMBPP-UHFFFAOYSA-N lacto-N-fucopentaose II Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(NC(C)=O)C(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)OC1CO FKADDOYBRRMBPP-UHFFFAOYSA-N 0.000 description 2
- CMQZRJBJDCVIEY-UHFFFAOYSA-N lacto-N-fucopentaose III Natural products OC1C(O)C(O)C(C)OC1OC1C(OC2C(C(O)C(O)C(CO)O2)O)C(CO)OC(OC2C(C(OC3C(OC(O)C(O)C3O)CO)OC(CO)C2O)O)C1NC(C)=O CMQZRJBJDCVIEY-UHFFFAOYSA-N 0.000 description 2
- SJQVFWDWZSSQJI-RIIJGTCGSA-N lacto-n-decaose Chemical compound C[C@@H]1[C@@H](C)[C@@H](C)[C@@H](CC)OC1OC1[C@@H](CC)OC(OC[C@@H]2[C@@H](C(OC3[C@@H](C(OC4[C@@H]([C@@H](C)[C@@H](C)[C@@H](CC)O4)C)[C@@H](C)[C@@H](CC)O3)N=C(C)O)[C@@H](C)C(OC3[C@H](OC(OCC4[C@@H](C(OC5[C@@H](C(OC6[C@@H]([C@@H](C)[C@@H](C)[C@@H](CC)O6)C)[C@@H](C)[C@@H](CC)O5)N=C(C)O)[C@@H](C)C(OC5[C@@H]([C@@H](C)C(C)O[C@@H]5C)C)O4)C)[C@H](N=C(C)O)[C@H]3C)CC)O2)C)[C@H](N=C(C)O)[C@H]1C SJQVFWDWZSSQJI-RIIJGTCGSA-N 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 229960004488 linolenic acid Drugs 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 238000001000 micrograph Methods 0.000 description 2
- 235000021239 milk protein Nutrition 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 235000020660 omega-3 fatty acid Nutrition 0.000 description 2
- 229940012843 omega-3 fatty acid Drugs 0.000 description 2
- ZDZMLVPSYYRJNI-CYQYEHMMSA-N p-lacto-n-hexaose Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1N=C(C)O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)OC([C@@H]1O)CO[C@H]1[C@@H]([C@H](C(O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)[C@@H](CO)O1)O)N=C(O)C)[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O ZDZMLVPSYYRJNI-CYQYEHMMSA-N 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035752 proliferative phase Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- SQVRNKJHWKZAKO-OQPLDHBCSA-N sialic acid Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@](O)(C(O)=O)OC1[C@H](O)[C@H](O)CO SQVRNKJHWKZAKO-OQPLDHBCSA-N 0.000 description 2
- 125000005630 sialyl group Chemical group 0.000 description 2
- 239000002356 single layer Substances 0.000 description 2
- 229940001941 soy protein Drugs 0.000 description 2
- 235000019408 sucralose Nutrition 0.000 description 2
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960000984 tocofersolan Drugs 0.000 description 2
- 235000021119 whey protein Nutrition 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- MJYQFWSXKFLTAY-OVEQLNGDSA-N (2r,3r)-2,3-bis[(4-hydroxy-3-methoxyphenyl)methyl]butane-1,4-diol;(2r,3r,4s,5s,6r)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.C1=C(O)C(OC)=CC(C[C@@H](CO)[C@H](CO)CC=2C=C(OC)C(O)=CC=2)=C1 MJYQFWSXKFLTAY-OVEQLNGDSA-N 0.000 description 1
- XZKUCJJNNDINKX-HGLHLWFZSA-N (2r,3s,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4s)-3,4,5-trihydroxy-5-(hydroxymethyl)oxolan-2-yl]methoxy]oxane-3,4,5-triol;hydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)C(O)(CO)O1 XZKUCJJNNDINKX-HGLHLWFZSA-N 0.000 description 1
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 1
- MKNNYTWMAUAKMA-FHHHURIISA-N (2s,4s,5r,6r)-5-acetamido-2-[(2s,3r,4s,5s,6r)-2-[(2r,3s,4r,5r)-5-amino-1,2,4-trihydroxy-6-oxohexan-3-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-4-hydroxy-6-[(1r,2r)-1,2,3-trihydroxypropyl]oxane-2-carboxylic acid Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](N)C=O)O[C@H](CO)[C@@H]1O MKNNYTWMAUAKMA-FHHHURIISA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- RWBRUCCWZPSBFC-UHFFFAOYSA-N 17-(1-hydroxyethyl)-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(O)C)C1(C)CC2 RWBRUCCWZPSBFC-UHFFFAOYSA-N 0.000 description 1
- MKNNYTWMAUAKMA-FRLIKFETSA-N 3'-Sialyllactosamine Chemical compound O1C([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](N)C=O)O[C@H](CO)[C@@H]1O MKNNYTWMAUAKMA-FRLIKFETSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 240000001592 Amaranthus caudatus Species 0.000 description 1
- 235000009328 Amaranthus caudatus Nutrition 0.000 description 1
- 244000247812 Amorphophallus rivieri Species 0.000 description 1
- 235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 235000001815 DL-alpha-tocopherol Nutrition 0.000 description 1
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 description 1
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 206010056340 Diabetic ulcer Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 229920002148 Gellan gum Polymers 0.000 description 1
- 229920002581 Glucomannan Polymers 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000569 Gum karaya Polymers 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010060231 Insect Proteins Proteins 0.000 description 1
- 229920001202 Inulin Polymers 0.000 description 1
- 229920002752 Konjac Polymers 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 108010070551 Meat Proteins Proteins 0.000 description 1
- 241000361919 Metaphire sieboldi Species 0.000 description 1
- OVRNDRQMDRJTHS-RTRLPJTCSA-N N-acetyl-D-glucosamine Chemical compound CC(=O)N[C@H]1C(O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-RTRLPJTCSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 208000013544 Platelet disease Diseases 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 239000004373 Pullulan Substances 0.000 description 1
- 229920001218 Pullulan Polymers 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000934878 Sterculia Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046996 Varicose vein Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010358 acesulfame potassium Nutrition 0.000 description 1
- 229960004998 acesulfame potassium Drugs 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 description 1
- 235000012735 amaranth Nutrition 0.000 description 1
- 239000004178 amaranth Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 239000008122 artificial sweetener Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 235000021324 borage oil Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 108010033929 calcium caseinate Proteins 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- 108010079058 casein hydrolysate Proteins 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 101150027376 chiA gene Proteins 0.000 description 1
- 235000019705 chickpea protein Nutrition 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000009852 coagulant defect Effects 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000001010 compromised effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 235000021196 dietary intervention Nutrition 0.000 description 1
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 description 1
- 235000020669 docosahexaenoic acid Nutrition 0.000 description 1
- 229940090949 docosahexaenoic acid Drugs 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 235000020673 eicosapentaenoic acid Nutrition 0.000 description 1
- 229960005135 eicosapentaenoic acid Drugs 0.000 description 1
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000008508 epithelial proliferation Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000019625 fat content Nutrition 0.000 description 1
- 235000013861 fat-free Nutrition 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000021323 fish oil Nutrition 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 230000009969 flowable effect Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 235000021255 galacto-oligosaccharides Nutrition 0.000 description 1
- 150000003271 galactooligosaccharides Chemical class 0.000 description 1
- 235000010382 gamma-tocopherol Nutrition 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 229940046240 glucomannan Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 description 1
- 229940029339 inulin Drugs 0.000 description 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 1
- 235000010494 karaya gum Nutrition 0.000 description 1
- 239000000231 karaya gum Substances 0.000 description 1
- 229940039371 karaya gum Drugs 0.000 description 1
- 239000000252 konjac Substances 0.000 description 1
- 235000010485 konjac Nutrition 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 229940057917 medium chain triglycerides Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 235000019895 oat fiber Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000013588 oral product Substances 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 235000020184 organic milk Nutrition 0.000 description 1
- 239000003346 palm kernel oil Substances 0.000 description 1
- 235000019865 palm kernel oil Nutrition 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 235000017924 poor diet Nutrition 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000004844 protein turnover Effects 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- 235000019423 pullulan Nutrition 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- SXMGGNXBTZBGLU-UHFFFAOYSA-N sialyllacto-n-tetraose c Chemical compound OCC1OC(OC2C(C(OC(C(O)CO)C(O)C(O)C=O)OC(CO)C2O)O)C(NC(=O)C)C(O)C1OC(C(C(O)C1O)O)OC1COC1(C(O)=O)CC(O)C(NC(C)=O)C(C(O)C(O)CO)O1 SXMGGNXBTZBGLU-UHFFFAOYSA-N 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 229940080237 sodium caseinate Drugs 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 229940071440 soy protein isolate Drugs 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- WPLOVIFNBMNBPD-ATHMIXSHSA-N subtilin Chemical compound CC1SCC(NC2=O)C(=O)NC(CC(N)=O)C(=O)NC(C(=O)NC(CCCCN)C(=O)NC(C(C)CC)C(=O)NC(=C)C(=O)NC(CCCCN)C(O)=O)CSC(C)C2NC(=O)C(CC(C)C)NC(=O)C1NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C1NC(=O)C(=C/C)/NC(=O)C(CCC(N)=O)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)CNC(=O)C(NC(=O)C(NC(=O)C2NC(=O)CNC(=O)C3CCCN3C(=O)C(NC(=O)C3NC(=O)C(CC(C)C)NC(=O)C(=C)NC(=O)C(CCC(O)=O)NC(=O)C(NC(=O)C(CCCCN)NC(=O)C(N)CC=4C5=CC=CC=C5NC=4)CSC3)C(C)SC2)C(C)C)C(C)SC1)CC1=CC=CC=C1 WPLOVIFNBMNBPD-ATHMIXSHSA-N 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 1
- 208000027185 varicose disease Diseases 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- 239000002478 γ-tocopherol Substances 0.000 description 1
- QUEDXNHFTDJVIY-DQCZWYHMSA-N γ-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-DQCZWYHMSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
Definitions
- the present invention relates to methods for promoting wound healing in a subject.
- the present invention also relates to nutritional compositions which employ beta-hydroxy-beta- methylbutyrate (HMB), arginine, glutamine, and at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO.
- HMB beta-hydroxy-beta- methylbutyrate
- HMO human milk oligosaccharide
- Hemostasis is defined as the mechanism that leads to cessation of bleeding from a blood vessel and involves multiple interlinked steps.
- blood vessels constrict in order to limit blood flow, which is then followed by platelets sealing and plugging the break in the wall of the blood vessel.
- Blood coagulation which is the final step of hemostasis, then occurs.
- the blood clot or thrombus serves to reinforce the plug created by the platelets.
- the inflammatory phase which is considered to be the defensive phase of wound healing in that it serves to both control bleeding and prevent infection, begins almost immediately after injury and typically lasts for a number of days thereafter.
- the inflammatory phase damaged cells, pathogens, and bacteria are removed from the wound site in order to prepare for the growth of new tissue.
- This phase of the healing process is normally associated with swelling, red skin, heat, and pain at the wound site.
- the proliferative phase of wound healing encompasses rebuilding the wound with new tissue.
- the proliferative phase is divided into three stages: filling the wound, contracting the wound margins, and covering the wound with epithelium, otherwise known as epithelialization.
- the wound closes.
- the tissue remodels and matures and the cells that had been used to repair the wound are removed by apoptosis.
- the maturation phase can last anywhere from several days to a year or more.
- necrosis for example, impedes wound healing because dead skin and foreign materials interfere with the healing process. Infections also delay wound healing because, rather than working to heal the wound, the body works to fight the infection.
- defects at particular stages of hemostasis such as platelet disorders, coagulation defects, and increased clot degradation, also affect the body’s ability to properly heal a wound.
- Age, diet, various medical conditions, and immobility also affect the wound healing process.
- the invention is directed to a method for promoting wound healing in a subject, comprising administering beta-hydroxy-beta-methylbutyrate (HMB), arginine, glutamine, and at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO to the subject in need thereof.
- HMB beta-hydroxy-beta-methylbutyrate
- HMO human milk oligosaccharide
- the present invention is directed to a nutritional composition, comprising HMB, arginine, glutamine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO.
- Fig. 1 shows the results of a fibroblast proliferation assay as described in the Example
- Fig. 2 shows digital micrographs of a monolayer of human dermal fibroblasts CCD1064Sk (ATCC® CRL2076TM) derived from normal male skin tissue, as described in the Example; and
- Fig. 3 shows a graphical representation of the extent of wound closure presented in the digital micrographs as described in the Example.
- compositions described in the present disclosure can comprise, consist of, or consist essentially of any of the elements and steps as described herein.
- ⁇ MB refers to beta- hydroxy- beta- methylbutyrate (also referred to as beta-hydroxyl-3-methyl butyric acid, beta-hydroxy isovaleric acid) and sources thereof. All weights, percentages, and concentrations as used herein to characterize HMB are based on the weight of HMB, regardless of source, unless otherwise specified.
- calcium HMB refers to the calcium salt of beta-hydroxy-beta-methylbutyrate (also referred to as beta-hydroxyl-3-methyl butyric acid, beta-hydroxy isovaleric acid, or HMB), which is most typically in a monohydrate form. All weights, percentages, and concentrations as used herein to characterize calcium HMB are based on the weight of calcium HMB monohydrate, unless otherwise specified.
- HMB beta-hydroxy-beta-methylbutyrate
- All weights, percentages, and concentrations as used herein to characterize calcium HMB are based on the weight of calcium HMB monohydrate, unless otherwise specified.
- human milk oligosaccharide or ⁇ MO”, as used herein, unless otherwise specified, refers generally to any one or more of a number of complex carbohydrates found in human breast milk that can be acidic or neutral in nature, and to precursors thereof.
- acidic HMO refers to HMOs that contain sialic acid, i.e., sialylated HMOs.
- neutral HMO refers to HMOs that lack sialic acid.
- nutritional product and “nutritional composition” as used herein, unless otherwise specified, refer to nutritional liquids and nutritional powders, the latter of which may be reconstituted to form a nutritional liquid, and are suitable for oral consumption by a human.
- promoting wound healing refers to obtaining an improved wound healing metric as compared with wound healing in the absence of the present methods and/or compositions.
- improved wound healing comprises increased wound closure and/or a reduction in the amount of time needed to complete wound healing.
- scratch assay and/or a cell-proliferation assay, such as an epithelial proliferation assay. Therefore, in a more specific embodiment, promotion of wound healing can be evidenced by increased fibroblast proliferation and/or migration.
- a method for promoting wound healing in a subject comprises administering HMB, arginine, glutamine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO to the subject.
- nutritional compositions are provided.
- the nutritional composition comprises HMB, arginine, glutamine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO.
- HMOs examples include N- acetylglucosamine (GlcNAc); L-fucose (L-Fuc); D-fucose (D-Fuc); fucosyl oligosaccharides (i.e.
- Lacto-N-fucopentaose I Lacto-N-fucopentaose II; Lacto-N-fucopentaose III; Lacto-N- difucohexaose I; and Lactodifucotetraose
- non-fucosylated, non-sialylated oligosaccharides i.e., Lacto-N-neotetraose
- sialyl fucosyl oligosaccharides i.e., 3'-Sialyl-3-fucosyllactose; Disialomonofucosyllacto-N-neohexaose; Monofucosylmonosialyllacto-N-octaose (sialyl Lea); Sialyllacto-N-fucohexaose II; Disialyllacto-N-fucopentaos
- glucose Glc at the reducing end is replaced by N-acetylglucosamine (e.g., 2'-fucosyl-N- acetylglucosamine (2'-FLNac) is such a variant to 2'-fucosyllactose).
- N-acetylglucosamine e.g., 2'-fucosyl-N- acetylglucosamine (2'-FLNac) is such a variant to 2'-fucosyllactose).
- HMOs include lacto-N-fucopentaose V, lacto-N-hexaose, para-lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-neohexaose, monofucosyllacto-N-hexaose II, isomeric fucosylated lacto-N-hexaose (1), isomeric fucosylated lacto-N-hexaose (3), isomeric fucosylated lacto-N-hexaose (2), difucosyl-para-lacto-N-neohexaose, difucosyl-para-lacto-N-hexaose, difucosyllacto-N-hexaose, lacto-N-neoocataose, para-lacto
- acidic HMOs that may be included individually or in combination in the compositions of the present invention include 3'-sialyl-3-fucosyllactose, disialomonofucosyllacto-N-neohexaose, monofucosylmonosialyllacto-N-octaose (sialyl Lea), sialyllacto-N-fucohexaose II, disialyllacto-N-fucopentaose II, monofucosyldisialyllacto-N-tetraose, 2'-sialyllactose (2’-SL), 2-sialyllactosamine (2-SL), 3'-sialyllactose (3’-SL), 3'-sialyllactosamine, 6'- sialyllactose (6’-SL), 6'-sialylactosamine, 6'-
- the neutral HMO comprises a fucosylated HMO and/or an N-acetylated HMO.
- fucosylated and N-acetylated HMOs that may be included individually or in combination in the compositions of the present invention include lacto-N-fucopentaose I, lacto-N-fucopentaose II, 2'-fucosyllactose (2’-FL), 3-fucosyllactose (3- FL), lacto-N-fucopentaose III, lacto-N-difucohexaose I, lactodifucotetraose, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 2'-fucosyl-N-acetylglucosamine (2'-FLNac), lacto-N- fucopentaose V, lacto
- the acidic HMO comprises 3’-SL, 6’-SL, or a combination thereof, and/or the neutral HMO comprises 2’-FL, 3-FL, LNT, LNnT, or a combination of two or more thereof.
- the acidic HMO comprises 6’-SL and/or the neutral HMO comprises 2’-FL, optionally in combination with at least one N-acetylated HMO, or more specifically, LNT and/or LNnT.
- the acidic HMO comprises 3’-SL and 6’-SL
- the neutral HMO comprises 2’-FL, 3-FL, and LNT.
- HMB is a naturally occurring amino acid metabolite that is known for use in a variety of nutritional products and supplements.
- HMB is a metabolite of the essential amino acid leucine and has been shown to modulate protein turnover and inhibit proteolysis.
- HMB is commonly used in nutritional products to help build or maintain healthy muscle in selected individuals, and a combination of HMB, arginine and glutamine have been found to promote wound healing in certain individuals, the present inventors have surprisingly discovered that HMB, in combination with arginine, glutamine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO, further promote wound healing.
- any source of HMB is suitable for use in the methods and nutritional compositions of the invention.
- HMB as the free acid, a salt, including an anhydrous salt or a hydrate salt, an ester, a lactone, or other product forms that otherwise provide a bioavailable form of HMB.
- the source of HMB is selected from the group consisting of alkali metal HMB, alkaline earth metal HMB, HMB free acid, HMB lactone and combinations of two or more thereof, or the HMB is selected from the group consisting of sodium HMB, potassium HMB, magnesium HMB, chromium HMB, calcium HMB and combinations of two or more thereof, or the HMB is calcium HMB monohydrate.
- the HMB, arginine, glutamine, the at least one acidic HMO, and the at the least one neutral HMO are administered to the subject orally.
- the HMB, arginine, glutamine, and the at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO are administered to the subject in a nutritional composition.
- the nutritional compositions further comprise one or more vitamins.
- suitable vitamins for use in the methods and nutritional compositions of the invention include vitamin B12, vitamin C, and/or vitamin E.
- Any vitamin E is suitable for use in the methods and compositions of the present invention, including, inter alia, d-alpha-tocopherol, dl-alpha-tocopherol, and gamma- tocopherol, and salts or esters thereof.
- the vitamin E is dl-alpha- tocopheryl acetate.
- the nutritional compositions further comprise one or more minerals as desired.
- the nutritional composition includes one or more minerals selected from the group consisting of zinc, calcium (to the extent the HMB source does not provide sufficient calcium), and a combinations thereof.
- the nutritional compositions further comprise zinc.
- the methods further comprise administering collagen to the subject.
- the nutritional compositions further comprise collagen. Any collagen protein that is suitable for use in nutritional compositions is contemplated for use in the present invention, including, inter alia, collagen from bones, skin, and connective tissue of animals, including cattle, fish, horses, pigs, or rabbits.
- the nutritional compositions further comprise carbohydrate.
- Suitable carbohydrates for use in the present invention include, inter alia, sugar, aspartame, acesulfame potassium, and combinations of two or more thereof.
- the HMB, arginine, glutamine, and the at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO are administered to the subject orally.
- the HMB , arginine, glutamine, and the at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO are provided in a nutritional composition, which can be administered to the subject orally.
- the nutritional compositions may be formulated and administered in any known or otherwise suitable oral product form, so long as they include HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO.
- HMB HMB
- glutamine glutamine
- arginine at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO.
- Any solid, liquid, semi-solid, semi-liquid or powder form, including combinations or variations thereof, are suitable for use in the methods described herein, provided that such forms allow for safe and effective oral delivery to the subject of the ingredients as also defined herein.
- the nutritional composition is in the form of a powder.
- the nutritional composition is in the form of a liquid.
- a serving size is from about 20 g to about 60 g, about 25 g to about 55 g, or about 45 g to about 50 g, to be administered as a powder or to be reconstituted in from about 1 ml to about 500 ml of liquid.
- a serving ranges from about 1 ml to about 500 ml, including from about 110 ml to about 500 ml, from about 110 ml to about 417 ml, from about 120 ml to about 500 ml, from about 120 ml to about 417 ml, from about 177 ml to about 417 ml, from about 207 ml to about 296 ml, from about 230 m to about 245 ml, from about 110 ml to about 237 ml, from about 120 ml to about 245 ml, from about 110 ml to about 150 ml, and from about 120 ml to about 150 ml.
- the serving is about 1 ml, or about 100 ml, or about 225 ml, or about 237 ml, or
- the HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO may be administered to the subject for a time period of at least 2 days, or at least 3 days, or at least 5 days, or at least 6 days, or at least 1 week, or at least 2 weeks, or at least 3 weeks, or at least 4 weeks, or at least 5 weeks, or at least 6 weeks, or at least 7 weeks, or at least 8 weeks, or at least 9 weeks, or at least 10 weeks, or at least 11 weeks, or at least 12 weeks, or at least 14 weeks, or at least 16 weeks, or at least 18 weeks, or at least 24 weeks or longer.
- the HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO are administered to a subject once or multiple times daily or weekly.
- the HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO are administered to the subject from about 1 to about 6 times per day or per week, or from about 1 to about 5 times per day or per week, or from about 1 to about 4 times per day or per week, or from about 1 to about 3 times per day or per week.
- the HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO are administered once or twice daily for a period of at least 2 days, at least 3 days, at least 4 days, at least 5 days or at least 6 days, or at least one week, at least two weeks, at least three weeks, or at least four weeks.
- the desired amounts of HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO may be administered in more than one serving or, more specifically, in two servings.
- Each serving is desirably administered as a single, undivided dose, although the serving may also be divided into two or more partial or divided servings to be taken at two or more times during the day.
- the methods of the present invention include continuous day after day administration, as well as periodic or limited administration, although continuous day after day administration is generally desirable.
- the subject is administered about 0.5 grams to about 55 grams, or about 0.5 grams to about 30 grams, or about 2.5 grams to about 30 grams, or about 2.5 grams to about 20 grams, or about 5 grams to about 15 grams per day of arginine, about 0.5 grams to about 55 grams, or about 0.5 grams to about 30 grams, or about 2.5 grams to about 30 grams, or about 2.5 grams to about 20 grams, or about 5 grams to about 15 grams per day of glutamine, about 0.001 to about 5500 mg, or about 0.01 to about 3000 mg, or about 0.01 to about 300 mg, or about 0.01 to about 75 mg per day of the acidic HMO, about 0.001 to about 5500 mg, or about 0.01 to about 3000 mg, or about 0.01 to about 300 mg, or about 0.01 to about 75 mg per day of the neutral HMO, and about 0.1 grams to about 10 grams, or about 0.1 grams to about 5 grams, or about 0.5 grams to about 5 grams, or about 0.5 grams to about 3 grams, or about or about 5 grams to about 3 grams, or or or about
- the subject is administered about 5 grams to about 15 grams per day of arginine, about 5 grams to about 15 grams per day of glutamine, about 0.01 to about 75 mg per day of the acidic HMO, about 0.01 to about 75 mg per day of the neutral HMO, and about 0.5 grams to about 1.5 grams per day of HMB.
- the subject is administered about 5 grams to about 15 grams per day of arginine, about 5 grams to about 15 grams per day of glutamine, and about 0.5 grams to about 1.5 grams per day of HMB.
- the nutritional composition comprises from about 0.04% to about 5%, from about 0.04% to about 2.5%, from about 0.2% to about 2.5%, or from about 0.2% to about 1.5% of HMB, based on the weight of the nutritional composition. In additional specific embodiments, the nutritional composition comprises from about 0.2 to about 1.5 wt % of HMB, based on the weight of the nutritional composition.
- the nutritional composition comprises from about 0.1 to about 50 wt %, about 0.1 to about 30 wt %, about 10 to about 50 wt %, or about 10 to about 30 wt % of arginine, based on the weight of the nutritional composition.
- the nutritional composition is a liquid and comprises from about 1 to about 5 wt % of arginine, based on the weight of the nutritional composition.
- the nutritional composition is a powder and comprises from about 20 to about 30 wt % of arginine, based on the weight of the nutritional composition.
- the nutritional composition comprises from about 0.1 to about 50 wt %, about 0.1 to about 30 wt %, about 10 to about 50 wt %, or about 10 to about 30 wt % of glutamine, based on the weight of the nutritional composition.
- the nutritional composition is a liquid and comprises from about 1 to about 5 wt % of glutamine, based on the weight of the nutritional composition.
- the nutritional composition is a powder and comprises from about 20 to about 30 wt % of glutamine, based on the weight of the nutritional composition.
- the nutritional composition comprises from about 0.0001 to about 2 wt %, about 0.001 to about 2 wt %, about 0.1 to about 1 wt %, about 0.2 to about 1 wt %, or about 0.25 to about 0.85 wt % of the acidic HMO, based on the weight of the nutritional composition. In a more specific embodiment, the nutritional composition comprises from about 0.2 to about 1 wt % of the acidic HMO, based on the weight of the nutritional composition.
- the nutritional composition comprises from about 0.0001 to about 2 wt %, about 0.001 to about 2 wt %, about 0.1 to about 1 wt %, about 0.2 to about 1 wt %, or about 0.25 to about 0.85 wt % of the neutral HMO, based on the weight of the nutritional composition. In a more specific embodiment, the nutritional composition comprises from about 0.2 to about 1 wt % of the neutral HMO, based on the weight of the nutritional composition.
- the nutritional composition comprises from 0.04% to about 5 wt%, or from about 0.2 to about 1.5 wt %, of HMB; from about 0.1 to about 50 wt %, or from about 1 to about 30 wt %, of arginine; from about 0.1 to about 50 wt %, or from about 1 to about 30 wt %, of glutamine; from about 0.0001 to about 2 wt %, or from about 0.001 to about 2 wt % of the acidic HMO; and from about 0.0001 to about 2 wt %, or from about 0.001 to about 2 wt % of the neutral HMO, all based on the weight of the nutritional composition.
- the nutritional composition comprises from 0.04% to about 5 wt%, or from about 0.2 to about 1.5 wt %, of HMB; from about 0.1 to about 50 wt %, or from about 1 to about 30 wt %, of arginine; and from about 0.1 to about 50 wt %, or from about 1 to about 30 wt %, of glutamine, all based on the weight of the nutritional composition.
- the nutritional composition in addition to the protein, carbohydrate and fat contents provided by the HMB, amino acids and HMOs, or other components mentioned above, the nutritional composition further comprise additional sources of protein, carbohydrate, and/or fat.
- additional sources of protein, carbohydrate, and/or fat can be used in embodiments of nutritional compositions described herein.
- the nutritional composition includes additional sources of protein, carbohydrate and fat.
- an additional source protein in the nutritional composition comprises whey protein concentrate, whey protein isolate, whey protein hydrolysate, milk protein concentrate, milk protein isolate, milk protein hydrolysate, organic milk protein concentrate, soy protein concentrate, soy protein isolate, soy protein hydrolysate, pea protein concentrate, pea protein isolate, pea protein hydrolysate, acid casein, sodium caseinate, calcium caseinate, potassium caseinate, casein hydrolysate, nonfat dry milk, condensed skim milk, L- Carnitine, L-Lysine, taurine, lutein, rice protein concentrate, rice protein isolate, rice protein hydrolysate, fava bean protein concentrate, fava bean protein isolate, fava bean protein hydrolysate, meat protein, potato protein, chickpea protein, canola protein, mung protein, quinoa protein, amaranth protein, chia protein, hemp protein, flax seed protein, earthworm protein, insect protein, or combinations of two or more thereof.
- the nutritional composition may comprise additional protein source(s) in an amount from about 1 wt% to about 30 wt% of the nutritional composition. More specifically, the additional protein source(s) may be present in an amount from about 1 wt% to about 25 wt% of the nutritional composition, including about 1 wt% to about 20 wt%, about 2 wt% to about 20 wt%, about 1 wt% to about 15 wt%, about 1 wt% to about 10 wt%, about 5 wt% to about 10 wt%, about 10 wt% to about 25 wt%, or about 10 wt% to about 20 wt% of the nutritional composition.
- the additional protein source(s) comprise from about 1 wt% to about 5 wt% of the nutritional composition, or from about 20 wt% to about 30 wt% of the nutritional composition.
- the additional carbohydrate source(s) in the nutritional composition comprise fiber, maltodextrin, corn maltodextrin, corn syrup, organic corn maltodextrin, corn syrup, corn syrup solids, sucralose, cellulose gel, cellulose gum, gellan gum, carrageenan, fructooligosaccharides, inositol, maltodextrin, hydrolyzed starch, glucose polymers, rice-derived carbohydrates, sucrose, glucose, lactose, honey, sugar alcohols, isomaltulose, sucromalt, pullulan, potato starch, galactooligosaccharides, oat fiber, soy fiber, corn fiber, gum arabic, sodium carboxymethylcellulose, methylcellulose, guar gum, locust bean gum, kon
- the nutritional composition may comprise additional carbohydrate source(s) in an amount from about 0.5 wt% to about 75 wt% of the nutritional composition. More specifically, the additional carbohydrate source(s) may be present in an amount from about 1 wt% to about 70 wt% of the nutritional composition, including about 5 wt% to about 70 wt%, about 5 wt% to about 65 wt%, about 5 wt% to about 50 wt%, about 5 wt% to about 40 wt%, about 5 wt% to about 30 wt%, about 5 wt% to about 25 wt%, about 10 wt% to about 65 wt%, about 20 wt% to about 65 wt%, about 30 wt% to about 65 wt%, about 40 wt% to about 65 wt%, about 40 wt% to about 70 wt%, or about 15 wt% to about 25 wt%, of the nutritional composition.
- fat and oil as used herein, unless otherwise specified, are used interchangeably to refer to lipid materials derived or processed from plants or animals. These terms also include synthetic lipid materials so long as such synthetic materials are suitable for oral administration to humans.
- the additional fat source(s) comprise coconut oil, fractionated coconut oil, soy oil, soy lecithin, corn oil, safflower oil sunflower oil, palm olein, canola oil monoglycerides, lecithin, canola oil, medium chain triglycerides, one or more fatty acids such as linoleic acid, alpha-linolenic acid, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, medium chain triglyceride oil (MCT oil), high gamma linolenic (GLA) safflower oil, palm oil, palm kernel oil, marine oil, fish oil, algal oil, borage oil, cottonseed oil, fungal oil, interesterified oil, transesterified oil, structured lipid, omega-3 fatty acid, or combinations of two or more thereof.
- fatty acids such as linoleic acid, alpha-linolenic acid, fractionated coconut oil, soy oil, corn oil,
- the omega-3 fatty acid is selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, arachidonic acid, and alpha-linolenic acid, and combinations of two or more thereof.
- concentration and relative amounts of the sources of protein, carbohydrate, and fat in the exemplary nutritional compositions can vary considerably depending upon, for example, the specific dietary needs of the intended user.
- the nutritional composition may also comprise one or more components to modify the physical, chemical, aesthetic, or processing characteristics of the nutritional composition or serve as additional nutritional components.
- additional components include preservatives, emulsifying agents (e.g., lecithin), buffers, sweeteners including artificial sweeteners (e.g., saccharine, aspartame, acesulfame K, sucralose), colorants, flavorants, thickening agents, stabilizers, and so forth.
- the nutritional composition has a neutral pH, i.e., a pH of from about 6 to 8 or, more specifically, from about 6 to 7.5. In more specific embodiments, the nutritional composition has a pH of from about 6.5 to 7.2 or, more specifically, from about 6.8 to 7.1.
- the nutritional compositions may be formed using any techniques known in the art.
- a powder product can be formed by dry blending ingredients.
- the nutritional compositions may be formed by preparing an aqueous solution comprising protein and carbohydrate, preparing an oil blend comprising fat and oil-soluble components, and mixing together the aqueous solution and the oil blend to form an emulsified liquid nutritional composition.
- the HMB, arginine, glutamine and HMOs may be added at any time as desired in the process, for example, to the aqueous solution or to the emulsified blend.
- the compositions may be spray-dried or otherwise dried, if a powder product is desired.
- the nutritional compositions are subjected to a heat treatment which provides sterilization sufficient to maintain microbiological stability of the compositions over a desired shelf-life.
- This Example demonstrates various improvements provided by the methods of the invention. Specifically, this Example evaluated the stimulatory effect of HMB, arginine, glutamine, and HMOs on fibroblast proliferation through MTT assays and on fibroblast migration in scratch assays.
- the first study employed the MTT cell proliferation assay.
- Human dermal fibroblasts CCD1064Sk (ATCC® CRL2076TM) derived from normal male skin tissue were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% (v/v) FBS, 2 mmol/l glutamine and 0.1 mg/ml penicillin. The cells were grown and maintained in an incubator at 37°C with 95% humidity and 5% of CO2. The cells were seeded in 48-well plates at a density of 15x10 3 cells/well.
- HMOs HMOs
- 5-HMOs HMOs
- Abound 5 mM of a mixture of HMB, arginine and glutamine comprising 5 pM HMB, 19.1 pM arginine, and 22.7 pM glutamine
- MTT reagent was diluted (1:100) in DMEM without FBS and 200 pL were added per well. Cells were incubated at 37°C for 45 min.
- Fig. 1 shows the percentage of cell proliferation for a Control - bar A at time 0; and after 48 hours: Control - bar B; 5 pM Abound - bar C; 0.1 g/L 5-HMOs - bar D; 0.5 g/L 5-HMOs - bar E; 5 g/L 5-HMOs - bar F; 0.1 g/L 5-HMOs and 5 pM Abound - bar G; 0.5 g/L 5-HMOs and 5 pM Abound - bar H; and 5 g/L 5-HMOs and 5 pM Abound - bar I.
- Human dermal fibroblasts CCD1064Sk (ATCC® CRL2076TM) derived from normal male skin tissue were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% (v/v) FBS, 2 mmol/l glutamine and 0.1 mg/ml penicillin. Cells were grown and maintained in an incubator at 37°C with 95% humidity and 5% of CO2.
- DMEM Dulbecco’s Modified Eagle’s Medium
- the CCD1064Sk cells were seeded in 12-well plates at a density of 15x10 s cells/well and were grown to confluent monolayer in DMEM. Cell monolayers were disrupted by scraping them with a sterile plastic pipette tip in the center of the well. Cells were washed twice with PBS to remove cellular debris and treated with 5 mM Abound (5 pM HMB, 19.1 pM Arg, 22.7 pM Gin), 5-HMOs (5 g/L) and a combination of 5 pM Abound and 5 g/L 5-HMOs. Treated cells were kept at 37°C for 24 h and photographs were captured with an inverted microscope equipped with a digital camera. Fig.
- FIG. 3 where bar A represents the Control, bar B represents 5 pM Abound, bar C represents 5 g/L 5-HMOs, and bar D represents 5 pM Abound and 5 g/L 5-HMOs.
- * represents p ⁇ 0.05 for Control vs Treatment, and a represents p ⁇ 0.05 for 5g/L 5- HMOs vs Abound and 5g/L 5-HMOs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
A method for promoting wound healing in a subject comprises administering beta-hydroxy- beta-methylbutyrate (HMB), arginine, glutamine, and at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO to the subject in need thereof. A nutritional composition comprises HMB, arginine, glutamine, and an HMO selected from the group consisting of an acidic HMO and a neutral HMO.
Description
METHODS AND COMPOSITIONS FOR PROMOTING WOUND HEALING
FIELD OF THE INVENTION
[0001] The present invention relates to methods for promoting wound healing in a subject. The present invention also relates to nutritional compositions which employ beta-hydroxy-beta- methylbutyrate (HMB), arginine, glutamine, and at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO.
BACKGROUND OF THE INVENTION
[0002] Wound healing is generally divided into four phases: the hemostasis phase, the inflammatory phase, the proliferation phase, and the maturation phase. Hemostasis is defined as the mechanism that leads to cessation of bleeding from a blood vessel and involves multiple interlinked steps. During hemostasis, blood vessels constrict in order to limit blood flow, which is then followed by platelets sealing and plugging the break in the wall of the blood vessel. Blood coagulation, which is the final step of hemostasis, then occurs. The blood clot or thrombus serves to reinforce the plug created by the platelets.
[0003] The inflammatory phase, which is considered to be the defensive phase of wound healing in that it serves to both control bleeding and prevent infection, begins almost immediately after injury and typically lasts for a number of days thereafter. During the inflammatory phase, damaged cells, pathogens, and bacteria are removed from the wound site in order to prepare for the growth of new tissue. This phase of the healing process is normally associated with swelling, red skin, heat, and pain at the wound site.
[0004] The proliferative phase of wound healing encompasses rebuilding the wound with new tissue. The proliferative phase is divided into three stages: filling the wound, contracting the wound margins, and covering the wound with epithelium, otherwise known as epithelialization.
[0005] Finally, during the maturation phase of wound healing, the wound closes. The tissue remodels and matures and the cells that had been used to repair the wound are removed by apoptosis. The maturation phase can last anywhere from several days to a year or more.
[0006] Unfortunately, there are a number of factors that can lead to impaired wound healing. Although this list is not exhaustive, some of these factors include necrosis, bleeding disorders, immobility, diet, medical conditions, age, medications, dryness, lifestyle choices, infection, and/or varicose veins. Necrosis, for example, impedes wound healing because dead skin and foreign materials interfere with the healing process. Infections also delay wound healing because, rather than working to heal the wound, the body works to fight the infection. In patients with bleeding disorders, defects at particular stages of hemostasis, such as platelet disorders, coagulation defects, and increased clot degradation, also affect the body’s ability to properly heal a wound. [0007] Age, diet, various medical conditions, and immobility also affect the wound healing process. For example, in patients with diabetes, vascular disease, or other conditions that are correlated with poor circulation and/or a compromised immune system, it becomes difficult for the body to deliver the proper nutrients to wounds. In elderly patients, wounds normally take longer to heal. Lifestyle choices, such as poor diet, prevent individuals from ingesting nutrients that are necessary for effective wound healing. It would therefore be advantageous to provide patients suffering from a lack of proper nutrition with appropriate nutrients to facilitate wound healing. [0008] While there are various treatment options available for patients suffering from impaired wound healing, for example cleaning the wound to remove debris, removing dead skin, treating signs of infection, and/or prescribing antibiotics, many of these treatment options involve invasive surgery, which carries a number of possible risks and complications. Further, increased antibiotic use is undesirable.
[0009] In view of the above limitations, it is desirable to provide methods and compositions that would promote wound healing in a simple and non-invasive manner. This is particularly true when
it comes to promoting wound healing following surgical incisions, radiotherapy-induced injuries, diabetic foot ulcers, burns, and/or other acute or chronic wounds.
[0010] Abbott Laboratories’ Juven® product, and nutritional compositions as described in US 10,064,835 B2, promote wound healing, and more particularly promote the healing of diabetic ulcers in individuals suffering from diabetes and having at least one of a serum albumin level of less than or equal to 4.0 g/dL and an Ankle-Brachial Index of less than 1.0. However, further improvements in wound healing in general are desired. Accordingly, methods for promoting wound healing are desirable, including, but not limited to, methods for healing wounds such as surgical incisions, radiotherapy-induced injuries, diabetic foot ulcers, burns, and/or other acute or chronic wounds. A nutritional intervention that can help promote wound healing is also desirable.
SUMMARY OF THE INVENTION
[0011] Accordingly, it is an object of the invention to provide a convenient means for promoting wound healing in a subject in need thereof.
[0012] In one embodiment, the invention is directed to a method for promoting wound healing in a subject, comprising administering beta-hydroxy-beta-methylbutyrate (HMB), arginine, glutamine, and at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO to the subject in need thereof.
[0013] In additional embodiments, the present invention is directed to a nutritional composition, comprising HMB, arginine, glutamine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO.
[0014] The methods for promoting wound healing, as well as the nutritional compositions according to the present invention, are advantageous in that they, for example, increase wound closure and/or reduce the amount of time needed to complete would healing, or otherwise promote wound healing, in a patient-convenient manner. These and additional objects and advantages of the invention will be more fully apparent in view of the following detailed description.
BREIF DESCRIPTION OF THE DRAWINGS
[0015] The Detailed Description will be more fully understood in view of the drawings, in which: [0016] Fig. 1 shows the results of a fibroblast proliferation assay as described in the Example; [0017] Fig. 2 shows digital micrographs of a monolayer of human dermal fibroblasts CCD1064Sk (ATCC® CRL2076™) derived from normal male skin tissue, as described in the Example; and
[0018] Fig. 3 shows a graphical representation of the extent of wound closure presented in the digital micrographs as described in the Example.
DETAILED DESCRIPTION
[0019] Specific embodiments of the invention are described herein. The invention can, however, be embodied in different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided to illustrate more specific features of certain aspects of the invention to those skilled in the art.
[0020] The terminology as set forth herein is for description of the embodiments only and should not be construed as limiting the disclosure as a whole. All references to singular characteristics or limitations of the present disclosure shall include the corresponding plural characteristic or limitation, and vice versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made. Unless otherwise specified, “a,” “an,” “the,” and “at least one” are used interchangeably. Furthermore, as used in the description and the appended claims, the singular forms “a,” “an,” and “the” are inclusive of their plural forms, unless the context clearly indicates otherwise.
[0021] To the extent that the term “includes” or “including” is used in the description or the claims, it is intended to be inclusive of additional elements or steps, in a manner similar to the term “comprising” as that term is interpreted when employed as a transitional word in a claim. Furthermore, to the extent that the term “or” is employed (e.g., A or B), it is intended to mean “A
or B or both.” When the “only A or B but not both” is intended, then the term “only A or B but not both” is employed. Thus, use of the term “or” herein is the inclusive, and not the exclusive use. When the term “and” as well as “or” are used together, as in “A and/or B” this indicates A or B as well as A and B.
[0022] The methods and compositions described in the present disclosure can comprise, consist of, or consist essentially of any of the elements and steps as described herein.
[0023] All ranges and parameters, including but not limited to percentages, parts, and ratios disclosed herein are understood to encompass any and all sub-ranges subsumed therein, and every number between the endpoints. For example, a stated range of “1 to 10” should be considered to include any and all sub-ranges beginning with a minimum value of 1 or more and ending with a maximum value of 10 or less (e.g., 1 to 6.1, or 2.3 to 9.4), and to each integer (1, 2, 3, 4, 5, 6, 7, 8, 9, and 10) contained within the range.
[0024] Any combination of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.
[0025] All percentages are percentages by weight unless otherwise indicated.
[0026] The term ΉMB” as used herein, unless otherwise specified, refers to beta- hydroxy- beta- methylbutyrate (also referred to as beta-hydroxyl-3-methyl butyric acid, beta-hydroxy isovaleric acid) and sources thereof. All weights, percentages, and concentrations as used herein to characterize HMB are based on the weight of HMB, regardless of source, unless otherwise specified.
[0027] The term “calcium HMB” as used herein, unless otherwise specified, refers to the calcium salt of beta-hydroxy-beta-methylbutyrate (also referred to as beta-hydroxyl-3-methyl butyric acid, beta-hydroxy isovaleric acid, or HMB), which is most typically in a monohydrate form. All weights, percentages, and concentrations as used herein to characterize calcium HMB are based on the weight of calcium HMB monohydrate, unless otherwise specified.
[0028] The term “human milk oligosaccharide” or ΉMO”, as used herein, unless otherwise specified, refers generally to any one or more of a number of complex carbohydrates found in human breast milk that can be acidic or neutral in nature, and to precursors thereof.
[0029] The term “acidic HMO” as used herein, unless otherwise specified, refers to HMOs that contain sialic acid, i.e., sialylated HMOs.
[0030] The term “neutral HMO” as used herein, unless otherwise specified, refers to HMOs that lack sialic acid.
[0031] The term “nutritional powder” as used herein, unless otherwise specified, refers to nutritional powders that are generally flowable particulates and that, in certain embodiments, are reconstitutable with an aqueous liquid, and which are suitable for oral administration to a human. [0032] The term “nutritional liquid” as used herein, unless otherwise specified, refers to nutritional products made in ready-to-drink liquid form and to nutritional liquids made by reconstituting nutritional powders described herein prior to use.
[0033] The terms “nutritional product” and “nutritional composition” as used herein, unless otherwise specified, refer to nutritional liquids and nutritional powders, the latter of which may be reconstituted to form a nutritional liquid, and are suitable for oral consumption by a human.
[0034] The term “promoting wound healing” as used herein, unless otherwise specified, refers to obtaining an improved wound healing metric as compared with wound healing in the absence of the present methods and/or compositions. In certain embodiments, improved wound healing comprises increased wound closure and/or a reduction in the amount of time needed to complete wound healing. Those of ordinary skill in the art are familiar with other means of assessing improved wound healing and such means may be used to evidence improved wound healing according to the invention, for example through the use of scratch assay and/or a cell-proliferation assay, such as an epithelial proliferation assay. Therefore, in a more specific embodiment, promotion of wound healing can be evidenced by increased fibroblast proliferation and/or migration.
[0035] In one embodiment, a method for promoting wound healing in a subject is provided. The method comprises administering HMB, arginine, glutamine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO to the subject. In additional embodiments of the invention, nutritional compositions are provided. According to one embodiment, the nutritional composition comprises HMB, arginine, glutamine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO.
[0036] Examples of HMOs that may be included in the compositions of the invention include N- acetylglucosamine (GlcNAc); L-fucose (L-Fuc); D-fucose (D-Fuc); fucosyl oligosaccharides (i.e. , Lacto-N-fucopentaose I; Lacto-N-fucopentaose II; Lacto-N-fucopentaose III; Lacto-N- difucohexaose I; and Lactodifucotetraose); non-fucosylated, non-sialylated oligosaccharides (i.e., Lacto-N-neotetraose); sialyl fucosyl oligosaccharides (i.e., 3'-Sialyl-3-fucosyllactose; Disialomonofucosyllacto-N-neohexaose; Monofucosylmonosialyllacto-N-octaose (sialyl Lea); Sialyllacto-N-fucohexaose II; Disialyllacto-N-fucopentaose II; Monofucosyldisialyllacto-N- tetraose); and sialyl oligosaccharides (i.e., 3'-Sialyllactose; 3-Sialyllactosamine; 6'-Sialyllactose; 6'-Sialyllactosamine; Sialyllacto-N-neotetraose c; Monosialyllacto-N-hexaose; Disialyllacto-N- hexaose I; Monosialyllacto-N-neohexaose I; Monosialyllacto-N-neohexaose II; Disialyllacto-N- neohexaose; Disialyllacto-N-tetraose; Disialyllacto-N-hexaose II; Sialyllacto-N-tetraose a; Disialyllacto-N-hexaose I; and Sialyllacto-N-tetraose b). Also useful are variants in which the glucose Glc at the reducing end is replaced by N-acetylglucosamine (e.g., 2'-fucosyl-N- acetylglucosamine (2'-FLNac) is such a variant to 2'-fucosyllactose). Other suitable examples of HMOs that may be included in the compositions according to the general inventive concepts include lacto-N-fucopentaose V, lacto-N-hexaose, para-lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N-neohexaose, monofucosyllacto-N-hexaose II, isomeric fucosylated lacto-N-hexaose (1), isomeric fucosylated lacto-N-hexaose (3), isomeric fucosylated lacto-N-hexaose (2), difucosyl-para-lacto-N-neohexaose, difucosyl-para-lacto-N-hexaose, difucosyllacto-N-hexaose, lacto-N-neoocataose, para-lacto-N-octanose, iso-lacto-N-octaose, lacto-N-octaose,
monofucosyllacto-neoocataose, monofucosyllacto-N-ocataose, difucosyllacto-N-octaose I, difucosyllacto-N-octaose II, difucosyllacto-N-neoocataose II, difucosyllacto-N-neoocataose I, lacto-N-decaose, trifucosyllacto-N-neooctaose, trifucosyllacto-N-octaose, trifucosyl-iso-lacto-N- octaose, lacto-N-difuco-hexaose II, sialyl-lacto-N-tetraose a, sialyl-lacto-N-tetraose b, sialyl-lacto- N-tetraose c, sialyl-fucosyl-lacto-N-tetraose I, sialyl-fucosyl-lacto-N-tetraose II, and disialyl-lacto- N-tetraose, and combinations thereof.
[0037] Specific non-limiting examples of acidic HMOs that may be included individually or in combination in the compositions of the present invention include 3'-sialyl-3-fucosyllactose, disialomonofucosyllacto-N-neohexaose, monofucosylmonosialyllacto-N-octaose (sialyl Lea), sialyllacto-N-fucohexaose II, disialyllacto-N-fucopentaose II, monofucosyldisialyllacto-N-tetraose, 2'-sialyllactose (2’-SL), 2-sialyllactosamine (2-SL), 3'-sialyllactose (3’-SL), 3'-sialyllactosamine, 6'- sialyllactose (6’-SL), 6'-sialyllactosamine, sialyllacto-N-neotetraose c, monosialyllacto-N- hexaose, disialyllacto-N-hexaose I, monosialyllacto-N-neohexaose I, monosialyllacto-N- neohexaose II, disialyllacto-N-neohexaose, disialyllacto-N-tetraose, disialyllacto-N-hexaose II, sialyllacto-N-tetraose a, disialyllacto-N-hexaose I, and sialyllacto-N-tetraose b, sialyl-fucosyl- lacto-N-tetraose I, sialyl-fucosyl-lacto-N-tetraose II. In specific embodiments of the methods and compositions of the invention, the at least one acidic HMO comprises 3’-SL, 6’-SL, or a combination thereof.
[0038] In other specific embodiments, the neutral HMO comprises a fucosylated HMO and/or an N-acetylated HMO. Specific non-limiting examples of fucosylated and N-acetylated HMOs that may be included individually or in combination in the compositions of the present invention include lacto-N-fucopentaose I, lacto-N-fucopentaose II, 2'-fucosyllactose (2’-FL), 3-fucosyllactose (3- FL), lacto-N-fucopentaose III, lacto-N-difucohexaose I, lactodifucotetraose, lacto-N-tetraose (LNT), lacto-N-neotetraose (LNnT), 2'-fucosyl-N-acetylglucosamine (2'-FLNac), lacto-N- fucopentaose V, lacto-N-hexaose, para-lacto-N-hexaose, lacto-N-neohexaose, para-lacto-N- neohexaose, monofucosyllacto-N-hexaose II, isomeric fucosylated lacto-N-hexaose (1), isomeric
fucosylated lacto-N-hexaose (3), isomeric fucosylated lacto-N-hexaose (2), difucosyl-para-lacto- N-neohexaose, difucosyl-para-lacto-N-hexaose, difucosyllacto-N-hexaose, lacto-N-neoocataose, para-lacto-N-octanose, iso-lacto-N-octaose, lacto-N-octaose, monofucosyllacto-neoocataose, monofucosyllacto-N-ocataose, difucosyllacto-N-octaose I, difucosyllacto-N-octaose II, difucosyllacto-N-neoocataose II, difucosyllacto-N-neoocataose I, lacto-N-decaose, trifucosyllacto-N-neooctaose, trifucosyllacto-N-octaose, trifucosyl-iso-lacto-N-octaose, lacto-N- difucohexaose II. In additional specific embodiments, the at least one neutral HMO comprises 2’- FL, 3-FL, LNT, LNnT, or a combination of two or more thereof.
[0039] In specific embodiments of the methods and compositions of the invention, the acidic HMO comprises 3’-SL, 6’-SL, or a combination thereof, and/or the neutral HMO comprises 2’-FL, 3-FL, LNT, LNnT, or a combination of two or more thereof. In a more specific embodiment of the methods and compositions of the invention, the acidic HMO comprises 6’-SL and/or the neutral HMO comprises 2’-FL, optionally in combination with at least one N-acetylated HMO, or more specifically, LNT and/or LNnT. In a more specific embodiment, the acidic HMO comprises 3’-SL and 6’-SL, and the neutral HMO comprises 2’-FL, 3-FL, and LNT.
[0040] The methods and nutritional compositions of the present invention employ HMB, which is a naturally occurring amino acid metabolite that is known for use in a variety of nutritional products and supplements. HMB is a metabolite of the essential amino acid leucine and has been shown to modulate protein turnover and inhibit proteolysis. While HMB is commonly used in nutritional products to help build or maintain healthy muscle in selected individuals, and a combination of HMB, arginine and glutamine have been found to promote wound healing in certain individuals, the present inventors have surprisingly discovered that HMB, in combination with arginine, glutamine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO, further promote wound healing.
[0041] Any source of HMB is suitable for use in the methods and nutritional compositions of the invention. Examples include HMB as the free acid, a salt, including an anhydrous salt or a hydrate
salt, an ester, a lactone, or other product forms that otherwise provide a bioavailable form of HMB. In specific embodiments of the methods and compositions of the invention, the source of HMB is selected from the group consisting of alkali metal HMB, alkaline earth metal HMB, HMB free acid, HMB lactone and combinations of two or more thereof, or the HMB is selected from the group consisting of sodium HMB, potassium HMB, magnesium HMB, chromium HMB, calcium HMB and combinations of two or more thereof, or the HMB is calcium HMB monohydrate.
[0042] In specific embodiments of the methods of the invention, the HMB, arginine, glutamine, the at least one acidic HMO, and the at the least one neutral HMO are administered to the subject orally. In a further specific embodiment, the HMB, arginine, glutamine, and the at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO are administered to the subject in a nutritional composition.
[0043] In specific embodiments of the methods and compositions of the invention, the nutritional compositions further comprise one or more vitamins. Non-limiting examples of suitable vitamins for use in the methods and nutritional compositions of the invention include vitamin B12, vitamin C, and/or vitamin E. Any vitamin E is suitable for use in the methods and compositions of the present invention, including, inter alia, d-alpha-tocopherol, dl-alpha-tocopherol, and gamma- tocopherol, and salts or esters thereof. In a specific embodiment, the vitamin E is dl-alpha- tocopheryl acetate.
[0044] In additional specific embodiments of the methods and compositions of the invention, the nutritional compositions further comprise one or more minerals as desired. In a specific embodiment, the nutritional composition includes one or more minerals selected from the group consisting of zinc, calcium (to the extent the HMB source does not provide sufficient calcium), and a combinations thereof. In a specific embodiment of the methods and compositions of the invention, the nutritional compositions further comprise zinc.
[0045] In additional specific embodiments of the methods of the invention, the methods further comprise administering collagen to the subject. In specific embodiments of the compositions of
the invention, the nutritional compositions further comprise collagen. Any collagen protein that is suitable for use in nutritional compositions is contemplated for use in the present invention, including, inter alia, collagen from bones, skin, and connective tissue of animals, including cattle, fish, horses, pigs, or rabbits.
[0046] In additional specific embodiments of the methods and compositions of the invention, the nutritional compositions further comprise carbohydrate. Suitable carbohydrates for use in the present invention include, inter alia, sugar, aspartame, acesulfame potassium, and combinations of two or more thereof.
[0047] As indicated above, in specific embodiments of the methods of the invention, the HMB, arginine, glutamine, and the at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO are administered to the subject orally. In a more specific embodiment, the HMB , arginine, glutamine, and the at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO are provided in a nutritional composition, which can be administered to the subject orally.
[0048] The nutritional compositions may be formulated and administered in any known or otherwise suitable oral product form, so long as they include HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO. Any solid, liquid, semi-solid, semi-liquid or powder form, including combinations or variations thereof, are suitable for use in the methods described herein, provided that such forms allow for safe and effective oral delivery to the subject of the ingredients as also defined herein. In specific embodiments of the methods and compositions of the invention, the nutritional composition is in the form of a powder. In other specific embodiments, the nutritional composition is in the form of a liquid.
[0049] When the nutritional composition is a powder, for example, in specific embodiments, a serving size is from about 20 g to about 60 g, about 25 g to about 55 g, or about 45 g to about 50
g, to be administered as a powder or to be reconstituted in from about 1 ml to about 500 ml of liquid.
[0050] When the nutritional composition is in the form of a liquid, for example, reconstituted from a powder or manufactured as a ready-to-drink product, in specific embodiments, a serving ranges from about 1 ml to about 500 ml, including from about 110 ml to about 500 ml, from about 110 ml to about 417 ml, from about 120 ml to about 500 ml, from about 120 ml to about 417 ml, from about 177 ml to about 417 ml, from about 207 ml to about 296 ml, from about 230 m to about 245 ml, from about 110 ml to about 237 ml, from about 120 ml to about 245 ml, from about 110 ml to about 150 ml, and from about 120 ml to about 150 ml. In specific embodiments, the serving is about 1 ml, or about 100 ml, or about 225 ml, or about 237 ml, or about 500 ml.
[0051] In accordance with the methods of the present invention, to promote wound healing, the HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO, may be administered to the subject for a time period of at least 2 days, or at least 3 days, or at least 5 days, or at least 6 days, or at least 1 week, or at least 2 weeks, or at least 3 weeks, or at least 4 weeks, or at least 5 weeks, or at least 6 weeks, or at least 7 weeks, or at least 8 weeks, or at least 9 weeks, or at least 10 weeks, or at least 11 weeks, or at least 12 weeks, or at least 14 weeks, or at least 16 weeks, or at least 18 weeks, or at least 24 weeks or longer. In specific embodiments of the methods of the invention, the HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO, are administered to a subject once or multiple times daily or weekly. In specific embodiments, the HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO, are administered to the subject from about 1 to about 6 times per day or per week, or from about 1 to about 5 times per day or per week, or from about 1 to about 4 times per day or per week, or from about 1 to about 3 times per day or per week. In other specific embodiments, the HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO, are administered once or twice daily for a period
of at least 2 days, at least 3 days, at least 4 days, at least 5 days or at least 6 days, or at least one week, at least two weeks, at least three weeks, or at least four weeks.
[0052] In specific embodiments of the methods of the invention, the desired amounts of HMB, glutamine, arginine, and at least one HMO selected from the group consisting of an acidic HMO and a neutral HMO, may be administered in more than one serving or, more specifically, in two servings. Each serving is desirably administered as a single, undivided dose, although the serving may also be divided into two or more partial or divided servings to be taken at two or more times during the day. The methods of the present invention include continuous day after day administration, as well as periodic or limited administration, although continuous day after day administration is generally desirable.
[0053] In specific embodiments of the methods of the invention, the subject is administered about 0.5 grams to about 55 grams, or about 0.5 grams to about 30 grams, or about 2.5 grams to about 30 grams, or about 2.5 grams to about 20 grams, or about 5 grams to about 15 grams per day of arginine, about 0.5 grams to about 55 grams, or about 0.5 grams to about 30 grams, or about 2.5 grams to about 30 grams, or about 2.5 grams to about 20 grams, or about 5 grams to about 15 grams per day of glutamine, about 0.001 to about 5500 mg, or about 0.01 to about 3000 mg, or about 0.01 to about 300 mg, or about 0.01 to about 75 mg per day of the acidic HMO, about 0.001 to about 5500 mg, or about 0.01 to about 3000 mg, or about 0.01 to about 300 mg, or about 0.01 to about 75 mg per day of the neutral HMO, and about 0.1 grams to about 10 grams, or about 0.1 grams to about 5 grams, or about 0.5 grams to about 5 grams, or about 0.5 grams to about 3 grams, or about 0.5 grams to about 1.5 grams per day of HMB. In further specific embodiments, the subject is administered about 5 grams to about 15 grams per day of arginine, about 5 grams to about 15 grams per day of glutamine, about 0.01 to about 75 mg per day of the acidic HMO, about 0.01 to about 75 mg per day of the neutral HMO, and about 0.5 grams to about 1.5 grams per day of HMB.
[0054] In further specific embodiments, the subject is administered about 5 grams to about 15 grams per day of arginine, about 5 grams to about 15 grams per day of glutamine, and about 0.5 grams to about 1.5 grams per day of HMB.
[0055] In further specific embodiments of the invention, the nutritional composition comprises from about 0.04% to about 5%, from about 0.04% to about 2.5%, from about 0.2% to about 2.5%, or from about 0.2% to about 1.5% of HMB, based on the weight of the nutritional composition. In additional specific embodiments, the nutritional composition comprises from about 0.2 to about 1.5 wt % of HMB, based on the weight of the nutritional composition.
[0056] In another specific embodiment, the nutritional composition comprises from about 0.1 to about 50 wt %, about 0.1 to about 30 wt %, about 10 to about 50 wt %, or about 10 to about 30 wt % of arginine, based on the weight of the nutritional composition. In a more specific embodiment, the nutritional composition is a liquid and comprises from about 1 to about 5 wt % of arginine, based on the weight of the nutritional composition. In an additional specific embodiment, the nutritional composition is a powder and comprises from about 20 to about 30 wt % of arginine, based on the weight of the nutritional composition.
[0057] In another specific embodiment of the invention, the nutritional composition comprises from about 0.1 to about 50 wt %, about 0.1 to about 30 wt %, about 10 to about 50 wt %, or about 10 to about 30 wt % of glutamine, based on the weight of the nutritional composition. In a more specific embodiment, the nutritional composition is a liquid and comprises from about 1 to about 5 wt % of glutamine, based on the weight of the nutritional composition. In an additional specific embodiment, the nutritional composition is a powder and comprises from about 20 to about 30 wt % of glutamine, based on the weight of the nutritional composition.
[0058] In other specific embodiments of the invention, the nutritional composition comprises from about 0.0001 to about 2 wt %, about 0.001 to about 2 wt %, about 0.1 to about 1 wt %, about 0.2 to about 1 wt %, or about 0.25 to about 0.85 wt % of the acidic HMO, based on the weight of the nutritional composition. In a more specific embodiment, the nutritional composition comprises
from about 0.2 to about 1 wt % of the acidic HMO, based on the weight of the nutritional composition.
[0059] In further specific embodiments of the invention, the nutritional composition comprises from about 0.0001 to about 2 wt %, about 0.001 to about 2 wt %, about 0.1 to about 1 wt %, about 0.2 to about 1 wt %, or about 0.25 to about 0.85 wt % of the neutral HMO, based on the weight of the nutritional composition. In a more specific embodiment, the nutritional composition comprises from about 0.2 to about 1 wt % of the neutral HMO, based on the weight of the nutritional composition.
[0060] In further specific embodiments of the compositions of the invention, the nutritional composition comprises from 0.04% to about 5 wt%, or from about 0.2 to about 1.5 wt %, of HMB; from about 0.1 to about 50 wt %, or from about 1 to about 30 wt %, of arginine; from about 0.1 to about 50 wt %, or from about 1 to about 30 wt %, of glutamine; from about 0.0001 to about 2 wt %, or from about 0.001 to about 2 wt % of the acidic HMO; and from about 0.0001 to about 2 wt %, or from about 0.001 to about 2 wt % of the neutral HMO, all based on the weight of the nutritional composition.
[0061] In an additional embodiment of the compositions of the invention, the nutritional composition comprises from 0.04% to about 5 wt%, or from about 0.2 to about 1.5 wt %, of HMB; from about 0.1 to about 50 wt %, or from about 1 to about 30 wt %, of arginine; and from about 0.1 to about 50 wt %, or from about 1 to about 30 wt %, of glutamine, all based on the weight of the nutritional composition.
[0062] In other specific embodiments of the invention, in addition to the protein, carbohydrate and fat contents provided by the HMB, amino acids and HMOs, or other components mentioned above, the nutritional composition further comprise additional sources of protein, carbohydrate, and/or fat. A wide variety of sources and types of protein, carbohydrate, and/or fat can be used in embodiments of nutritional compositions described herein. In a specific embodiment, the nutritional composition includes additional sources of protein, carbohydrate and fat.
[0063] In further specific embodiments, an additional source protein in the nutritional composition comprises whey protein concentrate, whey protein isolate, whey protein hydrolysate, milk protein concentrate, milk protein isolate, milk protein hydrolysate, organic milk protein concentrate, soy protein concentrate, soy protein isolate, soy protein hydrolysate, pea protein concentrate, pea protein isolate, pea protein hydrolysate, acid casein, sodium caseinate, calcium caseinate, potassium caseinate, casein hydrolysate, nonfat dry milk, condensed skim milk, L- Carnitine, L-Lysine, taurine, lutein, rice protein concentrate, rice protein isolate, rice protein hydrolysate, fava bean protein concentrate, fava bean protein isolate, fava bean protein hydrolysate, meat protein, potato protein, chickpea protein, canola protein, mung protein, quinoa protein, amaranth protein, chia protein, hemp protein, flax seed protein, earthworm protein, insect protein, or combinations of two or more thereof.
[0064] The nutritional composition may comprise additional protein source(s) in an amount from about 1 wt% to about 30 wt% of the nutritional composition. More specifically, the additional protein source(s) may be present in an amount from about 1 wt% to about 25 wt% of the nutritional composition, including about 1 wt% to about 20 wt%, about 2 wt% to about 20 wt%, about 1 wt% to about 15 wt%, about 1 wt% to about 10 wt%, about 5 wt% to about 10 wt%, about 10 wt% to about 25 wt%, or about 10 wt% to about 20 wt% of the nutritional composition. Even more specifically, the additional protein source(s) comprise from about 1 wt% to about 5 wt% of the nutritional composition, or from about 20 wt% to about 30 wt% of the nutritional composition. [0065] In other specific embodiments, the additional carbohydrate source(s) in the nutritional composition comprise fiber, maltodextrin, corn maltodextrin, corn syrup, organic corn maltodextrin, corn syrup, corn syrup solids, sucralose, cellulose gel, cellulose gum, gellan gum, carrageenan, fructooligosaccharides, inositol, maltodextrin, hydrolyzed starch, glucose polymers, rice-derived carbohydrates, sucrose, glucose, lactose, honey, sugar alcohols, isomaltulose, sucromalt, pullulan, potato starch, galactooligosaccharides, oat fiber, soy fiber, corn fiber, gum arabic, sodium carboxymethylcellulose, methylcellulose, guar gum, locust bean gum, konjac flour,
hydroxypropyl methylcellulose, tragacanth gum, karaya gum, gum acacia, chitosan, arabinoglactins, glucomannan, xanthan gum, alginate, pectin, low methoxy pectin, high methoxy pectin, cereal beta-glucans, psyllium, inulin, and combinations of two or more thereof.
[0066] The nutritional composition may comprise additional carbohydrate source(s) in an amount from about 0.5 wt% to about 75 wt% of the nutritional composition. More specifically, the additional carbohydrate source(s) may be present in an amount from about 1 wt% to about 70 wt% of the nutritional composition, including about 5 wt% to about 70 wt%, about 5 wt% to about 65 wt%, about 5 wt% to about 50 wt%, about 5 wt% to about 40 wt%, about 5 wt% to about 30 wt%, about 5 wt% to about 25 wt%, about 10 wt% to about 65 wt%, about 20 wt% to about 65 wt%, about 30 wt% to about 65 wt%, about 40 wt% to about 65 wt%, about 40 wt% to about 70 wt%, or about 15 wt% to about 25 wt%, of the nutritional composition.
[0067] The terms “fat” and “oil” as used herein, unless otherwise specified, are used interchangeably to refer to lipid materials derived or processed from plants or animals. These terms also include synthetic lipid materials so long as such synthetic materials are suitable for oral administration to humans.
[0068] In further specific embodiments, the additional fat source(s) comprise coconut oil, fractionated coconut oil, soy oil, soy lecithin, corn oil, safflower oil sunflower oil, palm olein, canola oil monoglycerides, lecithin, canola oil, medium chain triglycerides, one or more fatty acids such as linoleic acid, alpha-linolenic acid, fractionated coconut oil, soy oil, corn oil, olive oil, safflower oil, medium chain triglyceride oil (MCT oil), high gamma linolenic (GLA) safflower oil, palm oil, palm kernel oil, marine oil, fish oil, algal oil, borage oil, cottonseed oil, fungal oil, interesterified oil, transesterified oil, structured lipid, omega-3 fatty acid, or combinations of two or more thereof. In a specific embodiment, the omega-3 fatty acid is selected from the group consisting of eicosapentaenoic acid, docosahexaenoic acid, arachidonic acid, and alpha-linolenic acid, and combinations of two or more thereof.
[0069] The concentration and relative amounts of the sources of protein, carbohydrate, and fat in the exemplary nutritional compositions can vary considerably depending upon, for example, the specific dietary needs of the intended user.
[0070] The nutritional composition may also comprise one or more components to modify the physical, chemical, aesthetic, or processing characteristics of the nutritional composition or serve as additional nutritional components. Non-limiting examples of additional components include preservatives, emulsifying agents (e.g., lecithin), buffers, sweeteners including artificial sweeteners (e.g., saccharine, aspartame, acesulfame K, sucralose), colorants, flavorants, thickening agents, stabilizers, and so forth.
[0071] In specific embodiments, the nutritional composition has a neutral pH, i.e., a pH of from about 6 to 8 or, more specifically, from about 6 to 7.5. In more specific embodiments, the nutritional composition has a pH of from about 6.5 to 7.2 or, more specifically, from about 6.8 to 7.1.
[0072] The nutritional compositions may be formed using any techniques known in the art. In one embodiment, a powder product can be formed by dry blending ingredients. In another embodiment, the nutritional compositions may be formed by preparing an aqueous solution comprising protein and carbohydrate, preparing an oil blend comprising fat and oil-soluble components, and mixing together the aqueous solution and the oil blend to form an emulsified liquid nutritional composition. The HMB, arginine, glutamine and HMOs may be added at any time as desired in the process, for example, to the aqueous solution or to the emulsified blend. The compositions may be spray-dried or otherwise dried, if a powder product is desired. Typically, the nutritional compositions are subjected to a heat treatment which provides sterilization sufficient to maintain microbiological stability of the compositions over a desired shelf-life.
EXAMPLE
[0073] This Example demonstrates various improvements provided by the methods of the invention. Specifically, this Example evaluated the stimulatory effect of HMB, arginine, glutamine,
and HMOs on fibroblast proliferation through MTT assays and on fibroblast migration in scratch assays.
[0074] The first study employed the MTT cell proliferation assay. Human dermal fibroblasts CCD1064Sk (ATCC® CRL2076™) derived from normal male skin tissue were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% (v/v) FBS, 2 mmol/l glutamine and 0.1 mg/ml penicillin. The cells were grown and maintained in an incubator at 37°C with 95% humidity and 5% of CO2. The cells were seeded in 48-well plates at a density of 15x103 cells/well. After 24 h of incubation, cells were treated with an HMO mixture comprising 3’-SL, 6’-SL, 2’-FL, 3-FL, and LNT (“5HMOs” or “5-HMOs”) in amounts of 0.1, 0.5 and 5 g/L, or with 5 mM of a mixture of HMB, arginine and glutamine comprising 5 pM HMB, 19.1 pM arginine, and 22.7 pM glutamine (“Abound”), or with a combination of 5-HMOs and Abound for 48 h. After the treatment, MTT reagent was diluted (1:100) in DMEM without FBS and 200 pL were added per well. Cells were incubated at 37°C for 45 min. The supernatant was replaced with 200 pL acidic isopropanol to dissolve the formazan crystals. The absorbance was measured at 595 nm with a microplate reader Multiskan Spectrum (Thermo Labsystems). Absorbances from both treated and control cells were calculated and expressed as percentage of cell proliferation. The results are shown in Fig. 1.
[0075] Fig. 1 shows the percentage of cell proliferation for a Control - bar A at time 0; and after 48 hours: Control - bar B; 5 pM Abound - bar C; 0.1 g/L 5-HMOs - bar D; 0.5 g/L 5-HMOs - bar E; 5 g/L 5-HMOs - bar F; 0.1 g/L 5-HMOs and 5 pM Abound - bar G; 0.5 g/L 5-HMOs and 5 pM Abound - bar H; and 5 g/L 5-HMOs and 5 pM Abound - bar I. A synergistic and dose-dependent effect was found when fibroblasts were incubated with a combination of Abound plus increasing amounts of 5-HMOs. At the highest 5-HMOs dose assayed (5 g/L 5-HMOs + Abound, bar I), fibroblast proliferation was increased by 26% as compared with the untreated control. In Fig. 1, * represents p<0.05 for Control vs Treatment; # represents p<0.05 for Abound vs Abound + 5g/L 5-HMOs; and a represents p<0.05 for 5g/L 5-HMOs vs Abound+ 5g/L 5-HMOs.
[0076] The second study employed a scratch assay. Human dermal fibroblasts CCD1064Sk (ATCC® CRL2076™) derived from normal male skin tissue were grown in Dulbecco’s Modified Eagle’s Medium (DMEM) with 10% (v/v) FBS, 2 mmol/l glutamine and 0.1 mg/ml penicillin. Cells were grown and maintained in an incubator at 37°C with 95% humidity and 5% of CO2.
[0077] The CCD1064Sk cells were seeded in 12-well plates at a density of 15x10s cells/well and were grown to confluent monolayer in DMEM. Cell monolayers were disrupted by scraping them with a sterile plastic pipette tip in the center of the well. Cells were washed twice with PBS to remove cellular debris and treated with 5 mM Abound (5 pM HMB, 19.1 pM Arg, 22.7 pM Gin), 5-HMOs (5 g/L) and a combination of 5 pM Abound and 5 g/L 5-HMOs. Treated cells were kept at 37°C for 24 h and photographs were captured with an inverted microscope equipped with a digital camera. Fig. 2 presents the photographs. The wounded area was measured using Image J software (version 1.40 National Institutes of Health, Bethesda, MD, USA) and closure was expressed as a percentage of the initial wound size, as shown in Fig. 3, where bar A represents the Control, bar B represents 5 pM Abound, bar C represents 5 g/L 5-HMOs, and bar D represents 5 pM Abound and 5 g/L 5-HMOs. In Fig. 3, * represents p<0.05 for Control vs Treatment, and a represents p<0.05 for 5g/L 5- HMOs vs Abound and 5g/L 5-HMOs
[0078] Compared with the untreated controls, a synergistic effect was found when fibroblasts were incubated with a blend of Abound plus 5-HMOs (bar D in Fig. 3). At the dose assayed (5 g/L 5- HMOs + Abound), fibroblast migration capacity was enhanced by 28%.
[0079] While the present application has been illustrated by the description of embodiments thereof, and while the embodiments have been described in considerable detail, such descriptions are not intended to restrict or in any way limit the scope of the appended claims to such detail. Additional advantages and modifications will readily appear to those skilled in the art. Therefore, the invention, in its broader aspects, is not limited to the specific details, the representative methods or compositions, or illustrative examples shown and described. Accordingly, departures
may be made from such details without departing from the spirit or scope of the general inventive concept.
Claims
1. A method for promoting wound healing in a subject, the method comprising administering beta-hydroxy-beta-methylbutyrate (HMB), arginine, glutamine, and at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO.
2. The method of claim 1, wherein the acidic HMO comprises 3’-sialyllactose (3’-SL), 6’- sialyllactose (6’-SL), or a combination thereof, and/or the neutral HMO comprises 2’- fucosyllactose (2’-FL), 3-fucosyllactose (3-FL), lacto-N-tetraose (LNT) and lacto-N- neotetraose (LNnT), or a combination of two or more thereof.
3. The method of claim 2, wherein the acidic HMO comprises 6’-SL, and/or the neutral HMO comprises 2’-FL.
4. The method of claim 3, wherein the neutral HMO further comprises at least one N-acetylated HMO, or more specifically, lacto-N-tetraose (LNT) and/or lacto-N-neotetraose (LNnT).
5. The method of any one of claims 1-4, wherein the subject is administered about 0.5 grams to about 55 grams per day of arginine, about 0.5 grams to about 55 grams per day of glutamine, about 0.001 to about 5500 mg per day of the acidic HMO, about 0.001 to about 5500 mg per day of the neutral HMO, and about 0.1 gram to about 10 grams per day of
HMB.
6. The method of claim 5, wherein the subject is administered about 5 grams to about 15 grams per day of arginine, about 5 grams to about 15 grams per day of glutamine, about
0.01 to about 75 mg per day of the acidic HMO, about 0.01 to about 75 g per day of the neutral HMO, and about 0.5 grams to about 1.5 grams per day of HMB.
7. The method of any one of claims 1-6, wherein the HMB, arginine, glutamine, the acidic HMO, and/or the neutral HMO are administered to the subject orally.
8. The method of any one of claims 1-7, wherein the HMB, arginine, glutamine, the acidic HMO, and/or the neutral HMO are administered to the subject in a nutritional composition.
9. The method of any one of claims 1-8, wherein the HMB is selected from the group consisting of alkali metal HMB, alkaline earth metal HMB, HMB free acid, HMB lactone and combinations of two or more thereof, or the HMB is selected from the group consisting of sodium HMB, potassium HMB, magnesium HMB, chromium HMB, calcium HMB and combinations of two or more thereof, or the HMB is calcium HMB monohydrate.
10. The method of any one of claim 8 or claim 9, wherein the nutritional composition further comprises one or more vitamins.
11. The method of any one of claims 1-10, wherein the method further comprises administering collagen to the subject.
12. A nutritional composition comprising beta-hydroxy-beta-methylbutyrate (HMB), arginine, glutamine, and at least one human milk oligosaccharide (HMO) selected from the group consisting of an acidic HMO and a neutral HMO.
13. The nutritional composition of claim 12, wherein the acidic HMO comprises 3’-sialyllactose (3’-SL), 6’-sialyllactose (6’-SL), or a combination thereof, and/or the neutral HMO comprises 2’-fucosyllactose (2’-FL), 3-fucosyllactose (3-FL), lacto-N-tetraose (LNT) lacto-N-neotetraose (LNnT), or a combination of two or more thereof.
14. The nutritional composition of claim 12 or 13, wherein the acidic HMO comprises 6’-SL and/or the neutral HMO comprises 2’-FL.
15. The nutritional composition of claim 14, wherein the neutral HMO further comprises at least one N-acetylated HMO, or more specifically, lacto-N-tetraose (LNT) and/or lacto-N- neotetraose (LNnT).
16. The nutritional composition of any one of claims 12-15, wherein the nutritional composition comprises, based on the weight of the nutritional composition:
(a) from about 0.4 to about 5 wt %, or from about 0.2 to about 1.5 wt %, of HMB; and/or
(b) from about 0.1 to about 50 wt %, or from about 10 to about 30 wt %, of arginine; and/or
(c) from about 0.1 to about 50 wt %, or from about 10 to about 30 wt %, of glutamine; and/or
(d) from about 0.0001 to about 2 wt %, or from about 0.001 to about 2 wt %, of the acidic HMO; and/or
(e) from about 0.0001 to about 2 wt %, or from about 0.001 to about 2 wt %, of the neutral HMO.
17. The nutritional composition of any one of claims 12-16, wherein the HMB is selected from the group consisting of alkali metal HMB, alkaline earth metal HMB, HMB free acid, HMB lactone and combinations of two or more thereof, or the HMB is selected from the group
consisting of sodium HMB, potassium HMB, magnesium HMB, chromium HMB, calcium HMB and combinations of two or more thereof, or the HMB is calcium HMB monohydrate.
18. The nutritional composition of any one of claims 12-17, wherein the nutritional composition further comprises carbohydrate.
19. The nutritional composition of any one of claims 12-18, wherein the nutritional composition further comprises collagen.
20. The nutritional composition of any one of claims 12-19, wherein the nutritional composition further comprises zinc.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163176524P | 2021-04-19 | 2021-04-19 | |
US63/176,524 | 2021-04-19 | ||
US202263296548P | 2022-01-05 | 2022-01-05 | |
US63/296,548 | 2022-01-05 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022225779A1 true WO2022225779A1 (en) | 2022-10-27 |
Family
ID=81597883
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/024745 WO2022225779A1 (en) | 2021-04-19 | 2022-04-14 | Methods and compositions for promoting wound healing |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022225779A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013032674A1 (en) * | 2011-08-29 | 2013-03-07 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
WO2014100191A1 (en) * | 2012-12-18 | 2014-06-26 | Abbott Laboratories | Nutritional compositions comprising neuroprotective dietary oligosaccharides |
US10064835B2 (en) | 2012-01-11 | 2018-09-04 | Abbott Laboratories | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers |
-
2022
- 2022-04-14 WO PCT/US2022/024745 patent/WO2022225779A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013032674A1 (en) * | 2011-08-29 | 2013-03-07 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
US10064835B2 (en) | 2012-01-11 | 2018-09-04 | Abbott Laboratories | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers |
WO2014100191A1 (en) * | 2012-12-18 | 2014-06-26 | Abbott Laboratories | Nutritional compositions comprising neuroprotective dietary oligosaccharides |
Non-Patent Citations (3)
Title |
---|
GÜNDOGDU RIZA HALDUN ET AL: "Mixture of Arginine, Glutamine, and [beta]-hydroxy-[beta]-methyl Butyrate Enhances the Healing of Ischemic Wounds in Rats", vol. 41, no. 6, 31 July 2017 (2017-07-31), pages 1045 - 1050, XP009536912, ISSN: 1941-2444, Retrieved from the Internet <URL:http://journals.sagepub.com/doi/full-xml/10.1177/0148607115625221> [retrieved on 20160129], DOI: 10.1177/0148607115625221 * |
SAVAS SIPAHI ET AL: "The effect of oral supplementation with a combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine on wound healing: a retrospective analysis of diabetic haemodialysis patients", BMC NEPHROLOGY, BIOMED CENTRAL, LONDON, GB, vol. 14, no. 1, 12 January 2013 (2013-01-12), pages 8, XP021141163, ISSN: 1471-2369, DOI: 10.1186/1471-2369-14-8 * |
WILLIAMS JEREMY Z ET AL: "Effect of a specialized amino acid mixture on human collagen deposition", ANNALS OF SURGERY, J.B. LIPPINCOTT COMPANY, PHILADELPHIA, US, vol. 236, no. 3, 1 September 2002 (2002-09-01), pages 369 - 375, XP002789584, ISSN: 0003-4932, DOI: 10.1097/00000658-200209000-00013 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5118125B2 (en) | High calorie dietary supplement | |
RU2482705C2 (en) | High-energy liquid enteral nutritional composition | |
ES2344640T3 (en) | NUTRITIONAL COMPOSITIONS. | |
RU2529158C2 (en) | Liquid enteral food composition with low content of monovalent metal ions | |
WO2011065552A1 (en) | Nutritional composition beneficial to small intestine | |
JP2016520664A (en) | Cohesive liquid bolus containing molecules that impart viscoelasticity | |
NZ567217A (en) | Novel use of carbohydrates and compositions | |
DK2999357T3 (en) | ANTI-SUSPENSION COMPOSITION CONTAINING GAS MOTILITY | |
US10064835B2 (en) | Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers | |
WO2022225779A1 (en) | Methods and compositions for promoting wound healing | |
JP4889970B2 (en) | Hyperphosphatemia preparation | |
EP2928325A1 (en) | Nutritional composition with non digestible oligosaccharides | |
KR20060127874A (en) | Enteropathy ameliorating composition | |
AU2018361465A1 (en) | Protein-dense nutritional compositions for use in treating and/or preventing a condition linked to loss of muscle mass and/or strength | |
WO2022225786A1 (en) | Methods and compositions for improving muscle strength and/or reducing muscle loss | |
JP4634757B2 (en) | Emulsified liquid enteral nutrient | |
CN112675295A (en) | Blueberry powder compound solid preparation capable of preventing and improving osteoarthritis and preparation method and application thereof | |
WO2023027859A1 (en) | Methods and compositions for improving wound healing | |
JP2004166616A (en) | Health food | |
JP6942174B2 (en) | Skin composition | |
Sudha et al. | Carbohydrates, Proteins, and Amino Acids: As Natural Products and Nutraceuticals | |
JP2016521738A (en) | Aggregating liquid bolus containing bioactive substances | |
WO2023183767A1 (en) | Methods and compositions for increasing insulin sensitivity | |
US20230310538A1 (en) | Tissue repair and wound healing composition and method using low molecular weight hydrolyzed collagen | |
KR20240115620A (en) | Composition for Preventing and Treating Gout Comprising B. vulgatus as an effective ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22722601 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22722601 Country of ref document: EP Kind code of ref document: A1 |